Te p oti ni b ( M S C 2 1 5 6 1 1 9 J) Te p oti ni b He p atic I m p air me nt Tri al
M S 2 0 0 0 9 5- 0 0 2 8
C O N F I D E N T I A L
I N F O R M A T I O N1/ [ADDRESS_45965] a C T N u m ber N ot a p plica ble
Pri nci p al I n vesti g at ors
Orla n d o Cli nical Researc h Ce nter5 0 5 5 S. Ora n ge A veOrla n d o, F L 3 2 8 0 9, U S AP h o ne: E mail: 
Q P S M R A, L L C
6 2 8 0 S u nset Dri ve, S uite 6 0 0Mia mi, F L., 3 3 1 4 3, U S AP h o ne: E mail: 
S p o ns or E M D Ser o n o Researc h & De vel o p me nt I nstit ute, I nc, 4 5 A  Mi d dlese x  T ur n pi [INVESTIGATOR_2531],  Billerica,  M A 0 1 8 2 1,  U S A.
Me dical Res p o nsi ble:
Merc k K Ga A, Fra n kf urter Strasse 2 5 0, 6 4 2 9 3 
Dar msta dt, Ger ma n yP h o ne: M o bile: E mail: 
S p o ns or Le g al  Re prese nt ati ve i n t he E ur o pe a n U ni o nMerc k K G a AFra n kf urter Strasse [ADDRESS_45966] u d y Pr ot oc ol Versi o n 2 4  A pril 2 0 1 8 / Versi o n 2. [ADDRESS_45967] aces Versi o n 1 5  Marc h 2 0 1 7 / Versi o n 1. [ADDRESS_45968] N o. PI
[INVESTIGATOR_43914] (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N2/75- Confidential -
This document is the property of [COMPANY_006] KGaA, Darmstadt, [LOCATION_013], or one of its subsidiaries. It 
is intended for restricted use only and may not â€“ in full or part â€“ be passed on, reproduced, published or used without express permission of [COMPANY_006] KGaA, Darmstadt, [LOCATION_013], or its subsidiary. Copyright Â© [ADDRESS_45969] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N3/75Protocol Table of Contents
Protocol Table of Contents ..................................................................................................[ADDRESS_45970] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N4/[ADDRESS_45971]........................33
6.2 Dosage and Administration ................................................................33
6.3 Assignment to Treatment Groups.......................................................33
6.4 Noninvestigational Medicinal Products to be Used............................33
6.5 Concomitant Medications and Nondrug Therapi[INVESTIGATOR_014]/Interventions......[ADDRESS_45972] Compliance .........37
6.10 Blinding ..............................................................................................37
6.11 Emergency Unblinding.......................................................................37
6.12 Treatment of Overdose .......................................................................37
6.13 Medical Care of Subjects after End of Study .....................................37
7 Study Procedures and Assessments....................................................37
7.1 Schedule of Assessments....................................................................38
7.1.1 Screening Visit....................................................................................38
7.1.2 Treatment Period ................................................................................38
7.1.3 End of Study Visit/Early Termination Visit .......................................[ADDRESS_45973] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N5/757.[ADDRESS_45974] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N6/[ADDRESS_45975] Files ............................................................55
10.3 Investigator Site File and Archiving...................................................56
10.4 Monitoring, Quality Assurance and Inspection by [CONTACT_43948] ..........................................................................................56
10.5 Changes to the Clinical Study Protocol..............................................57
10.6 Clinical Study Report and Publication Policy ....................................57
10.6.1 Clinical Study Report .........................................................................57
10.6.2 Publication ..........................................................................................57
11 References Cited in the Text...............................................................57
12 Appendices .........................................................................................60
Appendix I: Contraceptive Guidance and Woman of Childbearing Potential........61
Appendix II: Signature [CONTACT_43996]....................63Signature [CONTACT_3490] â€“ Protocol Lead.........................................................................................64Signature [CONTACT_3490] â€“ Principal Investigators ...........................................................................65Signature [CONTACT_3490] â€“ Principal Investigators ...........................................................................66Sponsor Responsible Persons not Named on the Cover Page ...........................................67Appendix III: Protocol Amendments and List of Changes .......................................68Amendment #[ADDRESS_45976] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N7/75Table of In-Text Tables
Table 1 Schedule of Assessments: Part 1 and Part 2 .......................................15
Table 2 Child-Pugh Grades/Class of Hepatic Impairment ..............................25Table [ADDRESS_45977] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N8/75List of Abbreviations
AE Adverse event
ALBI Albumin-Bilirubin
ANOVA Analysis of variance
AUC Area under the plasma concentration-time curve
AUC extra% Area under the plasma concentration-time curve extrapolated from time t 
to infinity as a percentage of AUC 0-âˆž
AUC 0-240h Area under the plasma concentration-time curve from time zero to 240 hours postdose
AUC
0-t Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time at which the concentration is at or above LLOQ
AUC
0-âˆž Area under the plasma concentration-time curve from time zero to infinity
Î²-hCG Beta-human chorionic gonadotropin
BLQ Below the lower limit of quantitation
CI Confidence intervalCL/f Apparent to tal body clearance of drug from plasma following oral 
administration
C
max Maximum plasma concentration observed
c-Met Mesenchymal-epi[INVESTIGATOR_43915]-stimulating hormoneGCP Good Clinical PracticeHCC Hepatocellular carcinomaHGF Hepatocyte growth factorICH International Council for HarmonizationIMP Investigational medicinal product
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N9/75IRB Institutional Review Board
Î»Z Apparent terminal rate constant
LLOQ Lower limit of quantitation
MRAUC 0-âˆž Metabolite (MSC2571109 or MSC2571107) AUC 0-âˆž to tepotinib AUC 0-âˆž 
ratio
MRC max Metabolite (MSC2571109 or MSC2571107) C max to tepotinib C max ratio
NCI National Cancer InstituteNSCLC Non-small cell lung carcinomaODWG Organ Dysfunction Working GroupPD PharmacodynamicsP-gp P-glycoproteinPK PharmacokineticsQTcF Corrected QT intervals using Fridericiaâ€™s formulaSAE Serious adverse eventSMC Safety Monitoring CommitteeS[LOCATION_003]R Suspected unexpected serious adverse reactiont
1/2 Apparent terminal half-life
TEAE Treatment-emergent adverse eventTKI Tyrosine kinase inhibitorTPR Translocated promoter regiont
max Time to reach the maximum plasma concentration
VZ/f Apparent volume of distribution during the terminal phase following 
extravascular administration
WOCBP Woman of childbearing potential
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Te p oti ni b ( M S C 2 1 5 6 1 1 9 J) Te p oti ni b He p atic I m p air me nt Tri al
M S 2 0 0 0 9 5- 0 0 2 8
C O N F I D E N T I A L
I N F O R M A T I O N1 0/ [ADDRESS_45978] a C T N u m ber N ot a p plica ble
Pri nci p al I n vesti g at ors
Orla n d o Cli nical Researc h Ce nter
5 0 5 5 S. Ora n ge A ve
Orla n d o, F L 3 2 8 0 9, U S A
P h o ne:  
E mail:  
Q P S M R A, L L C6 2 8 0 S u nset Dri ve, S uite 6 0 0Mia mi, F L., 3 3 1 4 3, U S AP h o ne: 
E mail: 
S p o ns or E M D Ser o n o Researc h & De vel o p me nt I nstit ute, 
I n c,  4 5 A  Mi d dlese x  T ur n pi [INVESTIGATOR_2531],  Billerica,  M A 0 1 8 2 1, U S A.
Me dical Res p o nsi ble:
Merc k K Ga A, Fra n kf urter Strasse 2 5 0, 6 4 2 9 3 
Dar msta dt, Ger ma n yP h o ne: M o bile: E mail: 
S p o ns or Le g al Re prese nt ati ve i n t he E ur o pe a n U ni o nMerc k K Ga AFra n kf urter Strasse [ADDRESS_45979] N o.  PI
[INVESTIGATOR_43916] p oti ni b ( M S C 2 1 5 6 1 1 9 J) Te p oti ni b He p atic I m p air me nt Tri al
M S 2 0 0 0 9 5- 0 0 2 8
C O N F I D E N T I A L
I N F O R M A T I O N1 1/ [ADDRESS_45980] u d y ce nters/c o u ntries [ADDRESS_45981] u d y  ce nters  i n  t he  U S A:  
a n d .
Pl a n ne d st u d y peri o d
(first s u bject i n-l ast s u bject o ut)Ma y 2 0 1 8 (first s u bject scree ne d) t o Se pte m ber 2 0 1 8 (last s u bject last visit)
Tri al  Re gistr y N ot a p plica ble
O bjecti ves: 
Pri m ar y o bjecti ve
! T o assess t he p har mac o ki netics ( P K) of te p oti ni b ( M S C 2 1 5 6 1 1 9J) i n s u bjects wit h vari o us 
de grees of i m paire d he patic f u ncti o n (i n c o m paris o n t o healt h y s u bjects).
Sec o n d ar y o bjecti ves
! T o  f urt her  i n vesti gate  t he  P K of  te p oti ni b  a n d  its  meta b olites  M S C 2 5 7 1 1 0 9  a n d  
M S C 2 5 7 1 1 0 7 i n s u bjects wit h vari o us de grees of i m paire d he patic f u ncti o n (i n c o m paris o n 
t o healt h y s u bjects)
! T o assess safet y a n d t olera bilit y of te p oti ni b i n s u bjects wit h vari o us de grees of i m paire d 
he patic f u ncti o n (i n c o m paris o n t o healt h y s u bjects).
Met h o d ol o g y: T his is a P hase 1, t w o-sta ge d, o pe n-la bel st u d y t o i n vesti gate t he effect of 
vari o us  de grees  of  he patic  i m pair me nt  o n  t he  P K,  safet y  a n d  t olera bilit y  of  t he  mese nc h y mal- e pit helial tra nsiti o n fact or ge ne (c- Met) ki nase i n hi bit or, te p oti ni b.
Part 1 will i ncl u de s u bjects  wit h he patic i m pair me nt ( C hil d- P u g h class A [ 6 s u bjects] a n d 
C hil d- P u g h class B [ 6 s u bjects]) a n d a c o ntr o l gr o u p ( 6 healt h y s u bjects  matc he d 1: 1 t o 6 s u bjects wit h C hil d- P u g h class B  wit h re gar d t o a ge Â± 1 0 years, wei g ht Â± 1 0 k g, a n d sa me ge n der). All s u bjects will recei ve a si n gle d ose of [ADDRESS_45982] u d y is o pti o nal a n d, if c o n d ucte d,  will e val uate d oses a b o ve 5 0 0 m g u p t o 
1 0 0 0  m g i n 6 s u bjects wit h he patic i m pair me nt of eit her C hil d- P u g h class A or B. 
A Safet y M o nit ori n g C o m mittee ( S M C) ma y b e esta blis he d t o e val uate t he safet y a n d P K
res ults of Part 1 if t he o verall de vel o p me nt pr o gra m of te p oti ni b deci des t o use hi g her d oses t ha n 5 0 0 m g ( u p t o 1 0 0 0 m g) i n t he P hase [ADDRESS_45983] u dies. T he S M C will t he n ma ke a rec o m me n dati o n o n t he te p oti ni b d ose a n d w hic h p o p ulati o n ( C hil d- P u g h class A or B) t o be e nr olle d i n Part [ADDRESS_45984] N o.  PI[INVESTIGATOR_43917] (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N12/75Serial blood samples (PK and clinical laboratory assessments) and urine samples (clinical 
laboratory assessments) will be collected at specified timepoints. There is a PK sampling period of 2 weeks for healthy subjects and 3 weeks for hepatic impaired subjects.
The End of Study visit is planned on Day 15 for healthy subjects and on Day 22 for hepatic 
impaired subjects. An Early Termination visit will be conducted for subjects who withdraw prematurely. The same assessments as for the End of Study visit will be conducted at the Early Termination visit.
Planned number of subjects: Eighteen subjects in Part 1 and 6 subjects in Part 2.
Primary endpoints: 
!PK profile of tepotinib (plasma) in terms of AUC 0-t, AUC 0-âˆž, and C maxat Day 1 to Day 15 
(healthy subjects) or Day 22 (hepatic impaired subjects) calculated by [CONTACT_43949].
Secondary endpoints: 
!PK profile of tepotinib (plasma) in terms of t max, t1/2, CL/f, V Z/f, AUC extra% at Day 1 to 
Day 15 (healthy subjects) or Day 22 (hepatic impaired subjects) calculated by 
[CONTACT_43950]2571109 and MSC2571107 (plasma) in 
terms of AUC 0-t, AUC 0-âˆž, Cmax, tmax, t1/2, AUC extra% at Day 1 to Day 15 (healthy subjects) or 
Day 22 (hepatic impaired subjects) calculated by [CONTACT_43951], andMRAUC
0-âˆžand MRC max
!Occurrence of treatment-emergent adverse events, changes from baseline in laboratory 
safety tests, 12-lead electrocardiograms (ECG) morphology and time intervals (PR, QRS, 
RR, QT and corrected QT intervals using Fridericiaâ€™s formula [QTcF]), and vital signs.
Pharmacokinetics: Blood samples for PK analysis will be collected on Day 1 predose and 
0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, and 16.0 hours postdose, Day 2 at 24, 30, and 36 hours postdose, Day 3 at 48, 54, and 60 hours postdose, Day 4 (72 hours), Day 5 (96 hours), Day 6 (120 hours), Day 7 (144 hours), Day 8 (168 hours), Day 10 (216 hours), Day 13 (288 hours), Day 15 (336 hours), and Day 22 (504 hours postdose; hepatic impaired subjects only).
Other assessments: Throughout the study at specified timepoints treatment-emergent adverse 
events, changes from baseline in laboratory safety tests, 12-lead ECG morphology and time intervals (PR, QRS, RR, QT and QTcF), and vital signs will be assessed.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N13/75Diagnosis and key inclusion and exclusion criteria: Men and women (of nonchildbearing 
potential), 18 to 75 years (inclusive) of age, with a body mass index of 18 to 36 kg/m2
(inclusive) and a body weight â‰¥[ADDRESS_45985] given informed consent and are willing and able to comply with study 
procedures will be eligible for enrollment. Subjects with impaired hepatic function (Child-Pugh class A or Child-Pugh class B) and subjects with normal hepatic function will be eligible to enroll in the study. Healthy subjects will be excluded if they have hepatitis B or C or had a previous infection with hepatitis C treated with Sofosbuvir or other antiviral compounds, or any other clinically relevant disease, as considered by [CONTACT_737]. Subjects with impaired hepatic function will be excluded if they have primary biliary liver cirrhosis, nonstabilized chronic heart failure, hepatocarcinoma, hepatic encephalopathy (Grade III or IV), sepsis or gastrointestinal bleeding, or any other clinically relevant disease, as considered by [CONTACT_737].
Investigational Medicinal Product: dose/mode of administration/ dosing schedule: One 
single oral dose of 500 mg tepotinib tablets (Tablet Formulation 2) will be administered in Part [ADDRESS_45986].
Reference therapy: dose/mode of administration/dosing schedule: Not applicable
Planned study and treatment duration per subject: Each subject will receive a single
administration of the investigational medicinal product (IMP) on Day 1.
In both Part [ADDRESS_45987] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N14/75Statistical methods:
Sample size:
Pharmacokinetic studies, including subjects with impaired liver function, are usually 
exploratory by [CONTACT_6073]. Considering the CVs for the primary endpoints AUC 0-tand C maxof 
tepotinib, 20.4% and 22.8% respectively, 6 evaluable subjects per group will provide 80% power at alpha level of 0.05 for detecting a group difference of 44% (AUC
0-t) and 50% (C max), 
which is considered sufficient to meet the study objectives. Therefore, 18 subjects (3 groups x 6 subjects) should be included in Part 1 and 6 subjects in Part 2. 
Analysis of primary endpoints:
As the primary analysis, an analysis of variance (ANOVA) model including hepatic function 
group as a fixed effect will be applied to log-transformed tepotinib PK parameters AUC
0-t, 
AUC 0-âˆž, and C max. Differences between the hepatic impairment groups and matched control 
will be estimated together with their 90% CIs then back-transformed to the original scale for presentation. 
Additionally, a generalized linear model including hepatic function group and sex (gender) as 
fixed effects, age and weight as covariates, will be applied to the same primary PK parameters. A further covariate log(dose) will be introduced when Part 2 data is included.
All endpoints will be descriptively analyzed using summary statistics by [CONTACT_43952]. Graphical displays will be given, where appropriate.
Analysis of secondary endpoints:
For the secondary PK parameters AUC
0-t, AUC 0-âˆž,a n d  C maxof the tepotinib metabolites, the 
same analyses as defined for the primary endpoints will be performed.
Analysis of safety:
Safety data will be listed and descriptively summarized as appropriate.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N15/75Table 1 Schedule of Assessments: Part 1 and Part 2
Activity/Assessment Screening On Treatment
Study Week -4 to -1 1
Study Day -28 to -2 -1 1 2
Visit Number 0 1 2 3
Time (hh:mm)Pre-
dose0:00 0:15 0:30 0:45 1:00 1:30 2:00 3:00 4:00 6:00 8:00 10:00 12:00 16:00 24:00 30:00 36:[ADDRESS_45988] confinementiX X XXXXXXXXXXXX X X X X X
AE monitoring X X X X X X X X X X X X X X X X X X X X
Previous/concomitant 
medication and nondrug 
therapy/intervention 
monitoringX X X XXXXXXXXXXXX X X X X X
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N16/75Activity/AssessmentOn TreatmentEnd of Study for 
Healthy Subjects
/ Treatment visit 
for Hepatic 
Impaired 
SubjectsEnd of Study
for Hepatic 
Impaired Subjects
Study Week 1 2 3 4
Study Day 3 4 5 6 7 8 10 13 15 22
Visit Number 4 5 6 7 8 9 10 11 12 13
Time (hh:mm) 48:00 54:00 60:00 72:00 96:00 120:00 144:00 168:00 216:00 288:00 336:00 504:[ADDRESS_45989] confinementiXXX X
AE monitoring X X X X X X X X X X XkXl
Previous/concomitant 
medication and nondrug 
therapy/intervention 
monitoringX X XX XX XX X X XkXl
AE = adverse event; Î²-hCG = Beta-human chorionic gonadotropin; ECG = electrocardiogram; FSH = follicle-stimulating hormone; IMP = investigational me dicinal 
product; PK = pharmacokinetic.
a For hepatic insufficiency assessment in subjects with hepatic impairment only.
b Drug administration will occur [ADDRESS_45990] will contain approximately 500 calories and will be balanced in macronutrients (approximately 50% carbohy drates, 25% protein, and 
25% fat). The menu must be approved by [CONTACT_1034]. The subject will be expected to eat the entire meal. The percentage consumed will be recorded for 
all subjects. A deviation will be recorded if the subject eats less than 90% of the meal. Subjects will not be excluded from do sing if they are unable to 
complete the meal in full.
c When several procedures are scheduled at the same theoretical time, the following sequence should be followed: 12-lead ECG fol lowed by [CONTACT_43953], preceding the PK sampling which will be performed at the specified timepoint. 
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N17/75d The Tepotinib Free Fraction (TFF) sample will not be drawn separately; TFF will be analyzed from the PK back up sample.
e Height will be measured at Screening only. Body weight will be measured at Screening and at Day -1 only.
f Clinical laboratory tests comprise of clinical chemistry, hematological parameters, coagulation (at Screening and Day 1 only), ur inalysis, and other tests (at 
Screening and Day 1 only) as specified in  Table 4. Subjects should fast for [ADDRESS_45991] atus, FSH samples 
will be drawn at Screening.
h For all subjects, a negative cannabinoid (THC) result on drugs of abuse screening  is required to participate in the study. If the result is positive, the 
Principal Investigator [INVESTIGATOR_43918]. For subjects with hepatic impairment, a positive cannabinoid (THC) result  on drugs of abuse screening 
will not be exclusionary (at Screening or Day -1) if the subject uses cannabinoids on medical recommendation. In subjects with h epatic impairment, positive 
test for drugs used on medical recommendation will be not exclusionary.
i Subjects will be admitted in the morning of Day -[ADDRESS_45992] a foll ow-up visit on Day 15, with 
the following assessments: PK sampling, monitoring of AEs and previous/concomitant medication and nondrug therapy/intervention.
l Hepatic impaired subjects only.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Te p oti ni b ( M S C 2 1 5 6 1 1 9 J) Te p oti ni b He p atic I m p air me nt Tri al
M S 2 0 0 0 9 5- 0 0 2 8
C O N F I D E N T I A L
I N F O R M A T I O N1 8/ [ADDRESS_45993] u d y  will be s p o ns ore d b y: E M D Ser o n o Researc h & De vel o p me nt I nstit ute, I n c, 
4 5 A Mi d dlese x T ur n pi [INVESTIGATOR_2531], Billerica, M A 0 1 8 2 1, U S A. T he S p o ns orâ€™s le gal re prese ntati ve i n t he E U/ E E A is  Merc k K Ga A, Fra n kf urter Strasse [ADDRESS_45994] u d y ce nters ( h o s pi[INVESTIGATOR_307]- base d, i n patie nt, P hase 1 researc h ce nters) 
i n t he U S A: 
! , U S A
! , U S A
T he  Pri nci pal I n vesti gat ors,   ( Orla n d o  Cli nical  Researc h  Ce nter),  a n d  
 ( Q P S M R A, L L C)  will pr o vi de e x pert me dical i n p ut a n d a d vice relati n g t o 
st u d y desi g n a n d e xec uti o n a n d are res p o nsi ble f or t he re vie w a n d si g n off of t he cli nical st u d y
re p ort ( C S R). 
Si g nat ure pa ges f or t he Pr ot oc ol Lea d a n d t he Pri nci pal I n vesti gat ors as well as a list of S p o ns or 
res p o nsi ble pers o ns are i n A p pe n di x II.
A Safet y M o nit ori n g C o m mittee ( S M C) ma y be esta blis he d. If a n S M C is esta blis he d it will c o nsist 
of, b ut ma y n ot be li mite d t o, t he f oll o wi n g me m bers: t he Cli nical P har mac ol o gist, Pri nci pal I n vesti gat ors, S p o ns orâ€™s Me dical Res p o nsi ble, a n d t he S p o ns orâ€™s Gl o bal Dr u g Safet y Pr o d uct Lea d. A d h oc me m bers will be c o ns ulte d as nee de d a n d ma y i ncl u de, b ut is n ot restricte d t o, t he Bi ostatisticia n.  Details re gar di n g t he S M C res p o nsi bilities are pr o vi de d i n Secti o n  5. 1.
T he S p o ns or's Gl o bal Dr u g Safet y de part me nt or its desi g nate d re prese ntati ve will s u per vise dr u g 
safet y a n d t he ti meli ne f or re p orti n g of a d verse e ve nts ( A Es) a n d seri o us a d verse e ve nts ( S A Es) t o all c o ncer ne d parties i n acc or da nce wit h t he a p plica ble g ui deli nes, la ws, a n d re g ulati o ns.
T he S p o ns or will part ner wit h a c o ntract researc h or ga nizati o n ( C R O), t o c o n d uct t he cli nical part 
of t he st u d y i ncl u di n g st u d y set- u p, c o or di nati o n, m o nit ori n g, data ca pt ure, data ma na ge me nt, statistical a nal ysis, a n d C S R pre parati o n. A ce ntral la b orat or y will be use d f or cli nical la b orat or y a nal ysis. A testi n g la b orat or y will be res p o nsi ble f or a nal ysis of t he p har mac o ki netic ( P K) sa m ples. T he S p o ns or will s u per vise all o uts o urce d acti vities.
T he S p o ns or will arra n ge deli ver y of t he i n vesti gati o nal me dici nal pr o d uct (I M P) t o t he st u d y 
ce nters. 
La b orat or y sa m ple pr ocessi n g, ha n dli n g, a n d st ora ge i nstr ucti o ns as well as d ose pre parati o n a n d 
dis pe nsi n g details will be prese nte d i n se parate ma n uals w hic h will be pre pare d b y t he C R O i n c o or di nati o n wit h t he S p o ns or.
D o c u me nt N o.  
O bject N o.  PI
[INVESTIGATOR_43919] (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N19/753 Background Information
3.1 General Information
The mesenchymal-epi[INVESTIGATOR_43920] (c-Met) receptor tyrosine kinase is a cell surface 
receptor, capable of mediating pleiotropic effects, including cell migration, survival, and proliferation. Its ligand is the hepatocyte growth factor (HGF), also known as scatter factor (1). 
Under physiological conditions, c-Met regulates invasive growth and morphogenesis in multiple embryonic tissues, such as muscles, the nervous system, bones, and vascular system and is essential for development. c-Met/HGF have been implicated in carcinogenesis and metastatic tumor progression by [CONTACT_43954], cancer cell proliferation, migration, invasion, and conferring resistance to apoptosis. Activating c-Met point mutations and amplification as well as c-Met/HGF co-expression have been observed in a number of human tumors. Pharmacological interference with the HGF/c-Met axis is considered with increasing interest as a promising strategy to inhibit primary tumor growth and metastasis.
The resistance of advanced epi[INVESTIGATOR_43921]; however r ecent findings indicate that many solid tumors are 
â€œaddictedâ€ to particular activated kinases. 
Targeting such kinases with selective inhibitors represents a promising anticancer approach. The 
role of c-Met in tumor progression and metastatic dissemination makes it a privileged candidate for therapeutic intervention.
Given the important role of aberrant HGF/c-Met signaling in cancer, several different therapeutic 
strategies, aimed at inhibiting HGF/c-Met signaling, have been developed and are currently being evaluated in clinical studies. These include agents that directly inhibit HGF and/or its binding to c-Met, antibodies targeted at c-Met, and small-molecule c-Met tyrosine kinase inhibitors (1- 6).
Proof of concept has been shown in Phase 2 studies with onartuzumab (a monoclonal antibody against the c-Met receptor) in combination with erlotinib in subjects with stage IIIB/IV non-small cell lung carcinoma (NSCLC) with c-Met overexpressing tumors (7), and with rilotumumab (a 
monoclonal antibody against HGF) in combination with chemotherapy in advanced/metastatic gastro-esophageal cancer with c-Met overexpressing tumors (8).
The free base form of tepotinib (EMD 1160879) has an identical structure to tepotinib(MSC2156119J). Both compounds have been used in a number of pharmacological studies, yielding comparable results. Competition experiments and crystallographic studies indicate that tepotinib is a reversible adenosine triphosphate-competitive kinase inhibitor. The biochemical activity of tepotinib, measured with the recombinant human c-Met kinase domain and a peptide substrate, resulted in an average half maximal inhibitory concentration of 1.7 nM. Tepotinib (free base form) displayed high selectivity towards c-Met using in vitro kinase reactions. Using a panel of more than 100 different kinases, high doses of the free base form of tepotinib (10 micromolar [Î¼M]) inhibited only the oncogenic kinases ALK, Axl, Blk, Ron, and TrkB by > 50%, and blockade 
of these kinases is suggested to further support the antitumor activity of the free base form of tepotinib through c-Met kinase.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N20/75In vivo, the activity of both tepotinib and the free base form of tepotinib was demonstrated in 
tumor models with ligand independent c-Met activation (Gastric Hs746T, gastric MKN-45, NSCLC NCI-H441, NSCLC EBC-1) and in tumor models co-expressing HGF and c-Met(Glioblastoma U87MG, pancreatic carcinoma KP-4, liver cancer MHCC97H) as well as in translocated promoter region (TPR)-Met transformed murine fibroblasts. Tepotinib and the free base form of tepotinib significantly inhibited tumor growth and induced partial or complete regression of established EBC-1, Hs746T, MKN-45, NCI-H441, U87MG, KP-4, MHCC97H, and TPR-Met NIH3T3 tumors. The antitumor efficacy of the combination of tepotinib with cetuximab, erlotinib, sorafenib, and temozolomide was demonstrated in mouse xenograft models of NSCLC, glioblastoma, and hepatocellular carcinoma (HCC).The mechanism of action of tepotinib was investigated in vivo in a PK/pharmacodynamic (PD) study, conducted on Hs746T gastric cancer xenografts and the finding indicate that treatment with tepotinib induces cell cycle arrest and inhibition of tumor cell proliferation.
In primary PD studies, tepotinib potently inhibited c-Met kinase activity in a dose-dependent 
manner. This inhibitory effect was confirmed both in tumor cells expressing full-length c-Met upon stimulation with HGF, and in tumor cells in which c-Met was activated in a ligand independent manner, ie, in cells harboring c-Met gene amplification or expressing the oncogenic fusion protein, TPR-Met. Serum proteins only moderatel y interfered with the inhibitory activity of 
tepotinib, which persisted over a prolonged period of time. Tepotinib treatment of susceptible tumor cells inhibited cell survival and HGF-dependent cell migration in a dose-dependent manner. Both effects were associated with inhibition of c-Met activation. 
As of 30 September 2017, about 452 subjects had been exposed to tepotinib in 5 completed studies,
in healthy volunteers (EMR200095-002, EMR200095-007, and MS200095-0012; n=79 subjects), and in subjects with different solid tu mors (EMR200095-001 and EMR200095-003; n=161), and 
4 ongoing studies in subjects with HCC, or epi[INVESTIGATOR_43922] c-Met mutated NSCLC (EMR200095-004, EMR200095-005, EMR200095-006, and MS200095-0022). In the ongoing studies, subjects with HCC have received tepotinib as monotherapy and subjects with NSCLC received either tepotinib monotherapy or a combination with gefitinib in Phase 1 or Phase 1b/[ADDRESS_45995] been performed in 79 healthy volunteers. Healthy volunteers tolerated a single or 3 doses of tepotinib (different dose levels) well. All treatment-emergent adverse events (TEAEs) were mild to moderate, except for one Grade [ADDRESS_45996] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N21/75No SAEs were reported and no subject died. No clinically significant findings with regard to 
laboratory parameters, vital signs, and electrocardiograms (ECGs) including corrected QT intervals using Fridericiaâ€™s formula (QTcF) values were noted.
Volunteers enrolled in this study might be exposed to a potential risk, including pancreatic enzyme 
elevation. However, inclusion of healthy volunteers is justified when the administration of tepotinib is limited to a single dose or short term multiple administrations that will be given under close monitoring conditions to reduce the risk for untoward effects.
Asymptomatic elevations in serum lipase and amylase are considered as important potential risk 
for subjects administered tepotinib. These elevations were observed in 5 out of 78 healthy volunteers exposed to tepotinib and were mild to moderate in severity (exception: one Grade 3 lipase elevation). The asymptomatic increase of serum amylase/lipase was not associated with a pancreatitis.
Knowing that the inhibition of c-Met shows teratogenic effects in knockout mice, stringent criteria 
are applied to ensure exclusion of women of childbearing potential in this study. Only healthy women that are known to be postmenopausal or surgically sterile (ie, hysterectomy and oophorectomy) will be enrolled in this study (for details see  Appendix I) .
In order to further mitigate any risk, a close monitoring of the clinical laboratory parameters, ECG, and vital signs will be performed in all healthy volunteer studies. Volunteers will be admitted to the study site and remain resident there for at least [ADDRESS_45997] of clinical pharmacology studies.
Based on previous studies, the 500 mg once daily dose achieves c-Met inhibition â‰¥ 90% and results 
in sufficiently high steady state (trough) exposure levels in â‰¥90% of subjects to induce activity in 
tumors with varying degrees of sensitivity to c-Met inhibition. The 500 mg once daily dose is, 
therefore, considered to be safe and in the biologically active range.
Refer to the Investigatorâ€™s Brochure for further information about the nonclinical and clinical 
programs and Guidance for the Investigator.
3.2 Study Rationale
In a mass balance trial, 14C-MSC2156119 was moderately metabolized in human subjects and a 
total of 10 different Phase 1 and Phase 2 metabolites were found. Total radioactivity was also mainly eliminated via feces (~78%) while only about 14% was recovered in urine. In feces, roughly 45% of the administered dose could be related to parent drug. This indicates a high extent of active secretion (likely via bile), but unabsorbed drug as well as reduction of N-oxides and hydrolysis of the glucuronide to parent drug may have also c ontributed to this high recovery. Based on AUC
all
(which corresponds to the AUC 0-240h within the observation period), the M506 could be identified 
as major metabolite both with respect to European Medicines Agency (EMA) Guidance ICH M3(2) EMA/CPMP/ICH/286/1995 (4) and the draft Food and Drug Administration (FDA) 
Guidance for Industry â€“ Drug Interaction Studies (5). Ratios of geometric mean values of AUC
all
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N22/75of M506 to total radioactivity and to parent MSC2156119J compound were about 40.4% and 
74.9%, respectively. M506 is formed from MSC2156119J with a median t maxof 24 hours ranging 
from 24 to 60 hours and showed an apparent geometric mean half-life of 93 hours ranging from 66 to 145 hours estimated on concentration data from 4 subjects. Urinary excretion was identified as minor route of excretion with an average recovery in urine of only 13.6% (range 8.8% to 17.7%).
According to the hepatic impairment guidances (FDA Guidance for Industry 2003 (9), EMA
Guideline CPMP/EWP/2339/02 2005) it should be determined if alterations of excretory and 
metabolic activities by [CONTACT_43955].
Currently, enrolment of subjects into tepotinib HCC studies is restricted to subjects with mild 
hepatic impairment, ie, Child-Pugh class A.
This study will evaluate the PK and safety of tepotinib in subjects with mild (Child-Pugh class A) 
and moderate (Child-Pugh class B) hepatic impairment.
In most cases, HCC develops within an established background of chronic liver disease (70 to 90% 
of all patients) (10)  and patients with cirrhosis have the highest risk of developi[INVESTIGATOR_43923] (90 to 
95% of subjects who develop HCC have underlying cirrhosis) (11). It is therefore assumed that 
the results of this study in subjects with hepatic impairment are also applicable to patients with HCC, especially patients with Child-Pugh class B.
In Part 1 of the study, PK and safety of a single dose of 500 mg tepotinib will be assessed in 
subjects with mild (Child-Pugh class A) and moderate (Child-Pugh class B) hepatic impairment in comparison to healthy subjects. A higher dose than [ADDRESS_45998] team. In this case, the SMC will assess the results of Part 1 and make a recommendation on the tepotinib dose and which population (Child-Pugh class A or B) to be enrolled in Part 2. Healthy subjects will not be enrolled in Part [ADDRESS_45999] of the study specified in 
this protocol is considered justifiable. 
4 Study Objectives
4.1 Primary Objective
!To assess the PK of tepotinib in subjects with various degrees of impaired hepatic function (in
comparison to healthy subjects).
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N23/754.2 Secondary Objectives
!To further investigate the pharmacokinetics of tepotinib and its metabolites MSC2571109 and 
MSC2571107 in subjects with various degrees of impaired hepatic function (in comparison to 
healthy subjects)
!To assess safety and tolerability of tepotinib in subjects with various degrees of impaired 
hepatic function (in comparison to healthy subjects).
4.[ADDRESS_46000] of various degrees of 
hepatic impairment on the PK, safety and tolerability of the c-Met kinase inhibitor, tepotinib.
Part 1 will include subjects with hepatic impairment (Child-Pugh class A [6 subjects] and 
Child-Pugh class B [6 subjects]) and a control group (6 healthy subjects matched 1:[ADDRESS_46001] to age Â± 10 years, weight Â± 10 kg, and same gender). Allsubjects will receive a single dose of 500 mg tepotinib.
Part 2 of the study is optional and, if conducted, will evaluate doses above 500 mg up to 1000 mg
in 6 subjects with hepatic impairment of either Child-Pugh class A or B. 
An SMC may be established to evaluate the safety- and PK results of Part 1 if the overall 
development program of tepotinib decides to use higher doses than 500 mg (up to 1000 mg) in the Phase 2 or Phase 3 studies. The SMC will then make a recommendation on the tepotinib dose and which population (Child-Pugh class A or B) to be enrolled in Part 2 based on the safety- and PK results of Part 1. See  Figure 1 for a diagram of the study design.
Subjects will be screened from Day -28 to Day -2. Subjects will be admitted to the study center on Day -1 and will remain inpatient at the study center under medical supervision until discharge on the morning of Day 4. 
The treatment consists of a single-dose administr ation of 500 mg tepotinib on Day 1 in Part 1. The 
dose to be investigated in Part 2 will be determined by [CONTACT_43956]- and 
PK results of Part 1.
Serial blood samples (PK and clinical laboratory assessments) and urine samples (clinical 
laboratory assessments) will be collected at the timepoints provided in Table 1. There is a PK 
sampling period of [ADDRESS_46002] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N24/75prematurely. The same assessments as for the End of Study visit will be conducted at the Early 
Termination visit.
Figure 1 Design Diagram
Part 2 of the study is optional.
CSR = Clinical study report; HCC = Hepatocellular carcinoma; PK = Pharmacokinetic, SMC = Safety Monitoring 
Committee.
Document No.  
Object No.  EDEHIY
EDEHIHChild-Pugh A, n=6 
Child-Pugh B, n=6 
dose: 500mg 
Hea" hy Subjects , n=6 
matching to subjects with 
Child-Pugh B -dose : 500mg 
final CSR 
Project Team Decision if dose in HCC > 500mg is required 
Child-Pugh A orB 
n=6 
dose: up to 1000 mg 
Final Analysis 
of dataMt 
as Addendum to CSR Safety and PK 
not acceptab le 
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N25/755.[ADDRESS_46003] design for hepatic impairment studies, in line with the FDA and EMA guidances/guidelines. According to the hepatic impairment guidances (FDA Guidance for Industry 2003, EMA Guideline CPMP/EWP/2339/02 2005), [ADDRESS_46004] of 6 healthy subjects with normal hepatic function, matched 1:1 to the subjects with moderate (Child-Pugh class B) impaired hepaticfunction with regard to age Â± 10 years, weight Â± 10 kg, and same gender. 
Subjects with hepatic impairment will be assigned to a group of mild (Child-Pugh class A) or 
moderate (Child-Pugh class B) hepatic impairment at Screening by [CONTACT_43957]-Pugh system. See Table 2 and Table 3.
Table 2 Child-Pugh Grades/Class of Hepatic Impairment
Child-Pugh Score Child-Pugh Grade/Class Severity of Hepatic Impairment
5-[ADDRESS_46005] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N26/75Table 3 Child-Pugh Criteria
Points Scored for Observed Findings (14, 15, 16)
12 3
Encephalopathy gradeanone 1 or 2 or medically 
controlled c3 or 4 or medically
controlledc
Ascitesbabsent slight or medically 
controlled cModerate or medically 
controlled c
Serum bilirubin (mg/dL) < 2 2 to 3 > 3
Serum albumin (g/dL) > 3.5 2.8 to 3.5 < 2.8
International Normalized Ratio (INR) < 1.70 1.70 to 2.20 > 2.20
a Encephalopathy will be assessed by [CONTACT_43958]: 
Grade 0: normal consciousness, personality, neurological examination, electroencephalogram
Grade 1: restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cycles per second waves
Grade 2: lethargic, time-disoriented, inappropriate, asterixis, ataxia, slow triphasic wavesGrade 3: somnolent, stuporous, place-disoriented, hyperactive reflexes, rigidity, slower waves
Grade 4: unrousable coma, no personality/behavior, decerebrate, slow 2 to 3 cycles per second delta activity.
b Ascites will be assessed by [CONTACT_43959]: 
Absent: No ascites is detectable by [CONTACT_43960].Slight: Ascites palpi[INVESTIGATOR_42426], but ascites measurable by [CONTACT_42474].
Moderate: Ascites detectable by [CONTACT_42475][INVESTIGATOR_42427].
c Diagnosis and treatment of medically controlled subjects must be confirmed by [CONTACT_423]â€™s medical records.
The majority of healthy volunteers are not expected  to have measurable concentrations after Day 
15; therefore sampling until Day [ADDRESS_46006] of change in active liver size in subjects with hepatic impairment. Simulations using the population representatives indicate that the concentration reached after 21 days decline is attained in subjects with hepatic impairment about 1 to 2 days later, ie, the predicted difference between the healthy and subjects with moderate hepatic impairment.
Model limitations include non-consideration of possibly reduced metabolic enzyme expression. 
Of the number of physiological changes known to occur in subjects with hepatic impairment (size of active liver, plasma protein binding, blood fl ow, metabolizing enzymes), only the reduction of 
active hepatocytes could be implemented in the model. Thus the effect of hepatic impairment could be stronger than predicted. 
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N27/755.2.[ADDRESS_46007] of hepatic impairment on the exposure of tepotinib.
The rationale for including metabolites as secondary endpoints are as follows:M506 was identified as the only major circulating metabolite and contributes with a low extent to 
the overall activity. Its contribution to safety and tolerability is not evaluated by [CONTACT_43961], 
as tepotinib is developed under the ICH S9 guidance. 
M506 is formed from MSC2156119J with a median t
maxof [ADDRESS_46008] been included as 
secondary endpoints. MSC2571109 represents the major human plasma metabolite of tepotinib (64.6% of parent AUC
0-240h ), while MSC2571107 is a metabolite of less significance (4.54% of 
parent AUC 0-240h ). A bioanalytical assay is available, which analyzes tepotinib and the 
enantiomers.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N28/755.2.[ADDRESS_46009] been reported for a number of other tyrosine kinase inhibitors with molecular targets other than c-Met (eg, sunitinib, imatinib, sorafenib) and can therefore be regarded as a class effect. The underlying mechanism that causes the enzyme elevation is unknown. The pancreas was not identified as a potential target organ in animal toxicology studies. No pancreatitis has been reported so far.
Tepotinib was identified as a P-glycoprotein (P-gp) substrate, as well as an inhibitor of P-gp, 
BCRP, OCT1, OCT2, MATE1, and MATE2. Intestinal and systemic drug-drug interactions on the transporter level with relevance cannot be ruled out. In vitro drug transporter interaction studies revealed a pronounced inhibition of OCT1, OCT2, and MATE2 by [CONTACT_43962]257119A with the potential for clinically relevant drug-drug interactions considering its current mean exposure at steady state in clinical studies.
5.2.[ADDRESS_46010] b een selected for the inclusion of healthy subjects 
and subjects with mild (Child-Pugh class A) and moderate (Child-Pugh class B) impaired hepatic function. Women of childbearing potential are excluded from participation in the study.
5.[ADDRESS_46011]â€™s routine medical care, the Investigator will ensure that the subject or the subjectâ€™s legal representative has provided written informed consent following the procedure described in Section 9.2.
5.3.1 Inclusion Criteria
All subjects:
1. Men and women (of nonchildbearing potential), 18 to 75 years (inclusive) of age at Screening
2. Body mass index of 18 to 36 kg/m2(inclusive) with a body weight â‰¥ [ADDRESS_46012] 1 year, as confirmed by [CONTACT_43963] (FSH) assessments performed at Screening, or surgically sterile (ie, documented 
hysterectomy, documented bilateral salpi[INVESTIGATOR_1656], or documented bilateral oophorectomy). Pregnancy assessments will also be performed on female subjects at Screening and at admission to the study center
4. A male participant must agree to use a barrier method, and to have their female partners use
highly effective, medically acceptable methods of c ontraception (ie, methods with a failure 
rate of less than 1 % per year) as detailed in  Appendix I of this protocol during participation in 
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N29/75the study and for at least [ADDRESS_46013] at Screening and 
Day -1. For all subjects, a negative cannabinoid (THC) result on drugs of abuse screening is required to participate in the study. If the result is positive, the Principal Investigator [INVESTIGATOR_43918]. For subjects with hepatic impairment, a positive cannabinoid (THC) result on drugs of abuse screening will not be exclusionary (at Screening or Day -1) if the subject uses cannabinoids on medical recommendation. In subjects with hepatic impairment, positive test for drugs used on medical recommendation will be not exclusionary.
7. Negative human immunodeficiency virus [ADDRESS_46014] be able to understand the full nature and purpose of the study, including 
possible risks and adverse effects
9. Absence of acute hepatitis.
Subjects with normal hepatic function:
10. Healthy volunteers, as judged by [CONTACT_737]
11. Medical history without any ongoing clinically relevant findings as judged by [CONTACT_737]12. Physical examinations without any clinically relevant  findings as judged by [CONTACT_737].
Subjects with impaired hepatic function:
13. Subjects with mild (Child-Pugh class A) and moderate (Child-Pugh class B) impaired hepatic 
function at Screening
14. Subjects with confirmed cirrhosis (excluding primary biliary liver cirrhosis)
15. Systolic blood pressure in the range of [ADDRESS_46015] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N30/755.3.2 Exclusion Criteria
All subjects:
1. Subject has taken an investigative medication within [ADDRESS_46016], which could influence the gastrointestinal 
absorption or motility
5. A history of epi[INVESTIGATOR_002]6. A history of malignant diseases other than basalioma7. Clinically relevant allergies that require medical treatment, as judged by [CONTACT_737]8. Inability to refrain from alcohol intake during confinement. Subjects should not consume more 
than 14 (women) or 21 (men) units of alcohol a week (unit = 1 glass of wine (125 mL) = 
1 measure of spi[INVESTIGATOR_2120] = Â½ pi[INVESTIGATOR_43924])
9. Any other clinically relevant disease, which in the Investigatorâ€™s opi[INVESTIGATOR_43925]
10. Inability to communicate or cooperate with the Investigator (eg, language problem, illiterate, 
poor mental status) or to comply with the requirements of the entire study, including dietary restrictions
11. Smoking > 10 cigarettes per day, or equivalent use of other forms of nicotine (ie, patches, gum, 
chewing tobacco, vapi[INVESTIGATOR_007]) for the duration of the study
12. Antacid drugs, H2-blocker and proton pump inhibitors might affect the absorption of tepotinib. 
H2-blocker or proton pump inhibitors should be stopped 5 days prior to Day 1 until Day 2. Antacids should not be taken 1 hour before the IMP administration until 2 hours after the IMP administration.
13. Renal dysfunction (defined as creatinine clearance < 60 mL/minute, calculated by [CONTACT_43964]-Gault formula)
Healthy Subjects:
14. Presence of hepatitis B or hepatitis C or previous infection with hepatitis C, treated with 
Sofosbuvir or other antiviral compounds
15. Use of any medication, including multivitamin prepa rations, received within [ADDRESS_46017] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N31/75except the occasional use of paracetamol/acetaminophen or ibuprofen (not > 500 mg per day) 
within 7 days before Day 1 until the End of Study visit.
Subjects with impaired hepatic function:
16. Primary biliary liver cirrhosis
17. Nonstabilized chronic heart failure ([LOCATION_001] Heart Association Class III and IV)18. Hepatocarcinoma19. Hepatic encephalopathy Grade III and IV20. Sepsis or spontaneous bacterial peritonitis within the last 2 years prior to Screening21. Gastrointestinal bleeding within 30 days prior to or during Screening22. Esophageal varices > Grade II at Screening23. Acute hepatic failure of any etiology (including viral, toxic, or drug induced)24. Portosystemic shunt25. Current intake of any drug with dose dependent hepatotoxicity, such as 
paracetamol/acetaminophen (> 500 mg per day)
26. Change in used medication (prescribed by a physician or over-the-counter medication) other 
than for hepatic insufficiency within [ADDRESS_46018] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N32/755.[ADDRESS_46019] be withdrawn from the study if any of the following occur during the study:
!Subject withdrew consent
!Participation in another clinical study during the duration of this study
!Use of nonpermitted concomitant medications, as defined in Section 6.5. However, any 
medications that are considered necessary for the subjectâ€™s wellbeing may be given at the 
discretion of the Investigator
!Protocol noncompliance judged as significant by [CONTACT_737], including noncompliance to 
the required study considerations (eg, food/diet requirements)
!Subject lost to PK sampling
!Any event that unacceptably endangers the safety of the subject.
If there is a medical reason for the withdrawal, the subject will remain under the supervision of the 
Investigator until satisfactory health has returned or care has been transferred to the subjectâ€™s general practitioner or to a hospi[INVESTIGATOR_43926].
In case of premature withdrawal from the study, the assessments scheduled for the End of Study 
visit should be performed, if possible, with the focus on the most relevant assessments (see Table 1) . Regardless, the appropriate electronic case report form (eCRF) section should be 
completed.
Subjects who are withdrawn after IMP administration and are not evaluable will be replaced, as 
discussed by [CONTACT_43965].
5.[ADDRESS_46020] of the Health Authorities or if new safety or efficacy information leads to an unfavorable risk benefit judgment for the IMP. The Sponsor may discontinue the study if it becomes unjustifiable for medical or ethical reasons, for poor enrollment, or because of discontinuation of clinical development of theIMP or withdrawal of the IMP or comparator from the market for safety reasons.
The Health Authorities and Institutional Review Boards (IRBs) will be informed about the 
discontinuation of the study in accordance with applicable regulations.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N33/755.[ADDRESS_46021] and Other Drugs Used in 
the Study
The term â€œInvestigational Medicinal Productâ€ refers to an active substance or a placebo being 
tested or used as a reference therapy in a clinical study, including products that have a marketing 
authorization but are formulated, packaged, or administered differently from the authorized form, used for an unauthorized indication, or used to gain further information about the authorized form.
6.[ADDRESS_46022]
Tablet Formulation 2 (film-coated tablet formulation) of tepotinib will be used in this study. For Part 1, 500 mg tablets of Tablet Formulation 2 will be used. For Part 2, 100 mg tablets of Tablet 
Formulation 2 or a bioequivalent formulation may also be used for doses other than 500 mg or 1000 mg.
Tepotinib 100 mg and 500 mg film-coated tablets for Phase 1, 2 and 3 clinical studies contain the 
excipi[INVESTIGATOR_840] D-mannitol, silica colloidal anhydrous, crospovidone, magnesium stearate, and 
OpadryÂ® II pi[INVESTIGATOR_8745] (for 100 mg) or Opadry II y ellow (for 500 mg). The film-coated tablets are 
intended for oral administration.
6.[ADDRESS_46023] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N34/756.5 Concomitant Medications and Nondrug 
Therapi[INVESTIGATOR_014]/Interventions
All concomitant medications taken by [CONTACT_43966], from the date of signature [CONTACT_43997] a ppropriate section of the eCRF, noting the name, dose, 
duration and indication of each drug. Nondrug interventions and any changes to a concomitant medication or other intervention should also be recorded in the eCRF.
6.5.[ADDRESS_46024] welfare and will not interfere with the study medication may be given at the Investigatorâ€™s discretion.
Healthy Subjects
Occasional use of paracetamol/acetaminophen or ibuprofen (not > 500 mg per day) within [ADDRESS_46025], except the occasional 
use of paracetamol/acetaminophen or ibuprofen (> 500 mg per day is prohibited) within 7 days before Day 1 until the End of Study visit.
Hepatic Impaired Subjects:
Concomitant medication inducing or inhibiting P-gp, BCRP, OCT1, OCT2, MATE1, or MATE2
should be stopped from 5 days prior to Day 1 until the End of Study visit.
Current intake of any drug with dose dependent hepatotoxicity, such as paracetamol/
acetaminophen > 500 mg per day is not allowed. 
A change in the medication (prescribed by a physician or over-the-counter) used other than for 
hepatic insufficiency within [ADDRESS_46026] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N35/75The use of nonpermitted concomitant medications for any reason during the study must result in 
withdrawal of the subject from the study. However, any medications that are considered necessary for the subjectâ€™s wellbeing may be given at the discretion of the Investigator.
6.5.3 Other Interventions
All Subjects
Subjects are not allowed to smoke > 10 cigarettes per day, or equivalent use of other forms of 
nicotine (ie, patches, gum, chewing tobacco, vapi[INVESTIGATOR_007]) for the duration of the study. 
Subjects are required to refrain from alcohol intake during confinement. Subjects should not 
consume more than 14 (women) or 21 (men) units of alcohol a week (unit = 1 glass of wine (125 mL) = 1 measure of spi[INVESTIGATOR_2120] = Â½ pi[INVESTIGATOR_43924]).
Subjects will receive the IMP after they have completed a standard breakfast. Drug administration 
is [ADDRESS_46027] will containapproximately 500 calories and will be balanced in macronutrients (approximately 50% carbohydrates, 25% protein, and 25% fat). The menu must be approved by [CONTACT_1034]. The subject will be expected to eat the entire meal. Th e percentage consumed will be recorded for all 
subjects. A deviation will be recorded if the s ubject eats less than 90% of the meal. Subjects will 
not be excluded from dosing if they are unable to complete the meal in full.
6.5.4 Special Precautions
This study will be performed at 2 hospi[INVESTIGATOR_307]-based, inpatient, Phase 1 research centers with personnel trained in basic or immediate life support. Equipment and other agents (ie, epi[INVESTIGATOR_43927], etc.) will be available at the study center in case of allergic reactions.
6.5.[ADDRESS_46028] medical care will
be provided at the study center for all AEs encountered during the study.
For details on the management of AEs and adverse drug reactions, see Section  [IP_ADDRESS].
6.[ADDRESS_46029]
Packaging and labeling will be in accordance with Manufacture of Investigational Medicinal 
Products (Annex 13, Volume 4), applicable local regulatory requirements, and applicable Good Manufacturing Practice Guidelines.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N36/75Tepotinib tablets will be supplied in aluminum-aluminum blisters. The blisters will be packed in a 
suitable carton box labeled with (but not limited to) the following required information: study number, number of tablets per box, st orage conditions, the words â€œCaution: New Drug â€“ Limited 
by [CONTACT_4496] (or [LOCATION_002]) law to investigational useâ€, batch number, and the Sponsorâ€™s name.
6.[ADDRESS_46030] during the IMP administration visit. Detailed guidance will be provided in the pharmacy manual.
The IMP supplies will be recorded in a drug inventory and stored in a locked cabinet, protected 
from environmental extremes until used in the study. Tepotinib should be stored at or below 25Â°C. Any deviations from the recommended storage conditions should immediately be reported to the Sponsor specified in the pharmacy manual, and the medication should not be used until authorization has been received from the Sponsor.
6.[ADDRESS_46031] Accountability
The Investigator (or designee) is responsible for ensuring tepotinib (IMP) accountability, including reconciliation of drugs and maintenance of records.
!Upon receipt of the IMP, the responsible person will check for accurate delivery and 
acknowledge receipt by [CONTACT_43967]. A copy will be archived for the Investigator Site File
!The dispensing of the IMP will be recorded on the appropriate drug accountability forms so that accurate records will be available for verification at each monitoring visit
!Study center IMP accountability records will include the following:
!Confirmation of IMP receipt, in good condition and in the defined temperature range
!The inventory of IMP provided for the clinical study and prepared at the center
!The use of each dose by [CONTACT_6992]
!The disposition (including return, if applicable) of any unused IMP
!Dates, quantities, batch numbers, kit numbers, expi[INVESTIGATOR_31637], and the individual subject study 
numbers.
The study center should maintain records, which adequately document that subjects were provided the doses specified in this protocol, and all IMPs provided were fully reconciled.
Unused IMP must not be discarded or used for any purpose other than the present study. No IMP 
that is dispensed to a subject may be redispensed to a different subject.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N37/75A Study Monitor will periodically collect the IMP accountability forms.
At the conclusion or termination of this trial, all used and unused IMP kits will be destroyed at the 
trial site according to local regulations and institutional guidelines. All used and unused medications will be carefully recorded and documented before destruction.
6.[ADDRESS_46032] Compliance
The IMP will be administered by [CONTACT_43968]. A 
mouth and hand check will be performed after administration of the IMP to ensure that the dose has been swallowed.
6.10 Blinding
Blinding is not applicable. (Note: the bioanalytical assay will be performed without knowledge of hepatic function group information. Access to hepatic function group information will be restricted and defined in a Data Access Plan).
6.[ADDRESS_46033] identifier (see Section 9.3)  will be assigned for each subject for who provided written 
informed consent. 
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N38/75Subjects are not allowed to have participated in a clinical study within the 30 days prior to 
administration of IMP.
All efforts should be made to perform assessments as close as possible to the scheduled timepoints.Subjects will be admitted to the study center on Day -1 and remain resident at the study center 
until the morning of Day 4, after completion of the Day 4 assessments.
When several procedures are scheduled at the same theoretical time, the following sequence should 
be followed: 12-lead ECG followed by [CONTACT_43969], preceding the PK sampling which will be performed at the specified timepoint. Therefore, assessments not performed at the exact timepoint are not to be considered protocol deviations as long as the actual collection date and time is recorded. Every effort should be made to perform assessments at the appropriate timepoint.
7.[ADDRESS_46034] information and informed consent form for review. 
After written informed consent is obtained for all procedures in the study, subjects will be 
evaluated for entry into the study according to the inclusion and exclusion criteria (Section  5.3) . 
Screening procedures specified in the Schedule of Assessments for Part 1 and Part 2 (Table 1)
must be performed and evaluated during Days -[ADDRESS_46035] meets all of the protocol inclusion criteria and none of the exclusion criteria, he/she 
will be considered as eligible and will be enrolled into the clinical study.
Subjects who fail to meet the protocol specified criteria for dosing, who withdraw from the study
or who withdraw their consent in the Screening period are considered screening failures. The following data, as a minimum, should be recorded for these subjects: date of informed consent, 
inclusion/exclusion criteria, demographics (including age, sex (gender), weight, and height), AEs (if any) from the date of informed consent until the subject is considered a screen failure by [CONTACT_737], reason for screening failure, and the Investigatorâ€™s signature. Rescreening for eligibility of subjects who failed the initial screeni ng will be allowed once per subject within the 
[ADDRESS_46036]â€™s medical hist ory, possible AEs, concomitant medication use
and inclusion/exclusion criteria, to ensure the subject remains eligible for participation in the study, 
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N39/75should be performed prior to admission to the study center, on Day -1. Eligible subjects will 
participate in Part 1 of the study. Subjects will receive their respective IMP dose on Day 1. Subjects will be discharged from the study center on the morning of Day 4, after completion of the Day 4 assessments.
Part 2 of the study is optional. Details are provided in Section  5.1.
Specific assessments to be performed during the treatment periods are presented in the Schedule 
of Assessments (Table 1) .
7.1.3 End of Study Visit/Early Termination Visit
Healthy subjects will partake in the End of Study visit on Day 15 and hepatic impaired subjects will partake in the End of Study visit on Day 22. Assessments at the End of Study visit are specified in the Schedule of Assessments for Part 1 and Part 2 (Table 1) . Subjects who discontinue from the 
study for any reason prior to the End of Study visit must undergo an Early Termination visit immediately upon discontinuation. Assessments at the Early Termination visit are the same as for the End of Study visit.
7.2 Demographic and Other Baseline Characteristics
7.2.1 Demographics
At Screening, the following demographic data w ill be collected: date of birth, sex (gender), weight, 
height, race, and ethnicity.
Demographic data collected at Screening will be recorded in the eCRF. 
7.2.[ADDRESS_46037]â€™s medical hist ory (including the hepatic insufficiency) should be 
performed at Screening to determine the subjectâ€™s eligibility. An update of medical history will be 
performed at admission to the study center on Day -1. At Screening, subjects with hepatic impairment will be allocated to the mild (Child-Pugh class A) and moderate (Child-Pugh class B) hepatic impairment group according to the Child-Pugh classification as specified in  Table [ADDRESS_46038] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N40/75be assessed at timepoints as specified in the Schedule of Assessments for Part 1 and Part 2
(Table 1) .
7.[ADDRESS_46039] (see Section [IP_ADDRESS]) . 
The reporting period for AEs is described in Section  [IP_ADDRESS].
7.4.1 Adverse Events
[IP_ADDRESS] Adverse Event Definitions
Adverse Event
An AE is any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product, regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. 
For surgical or diagnostic procedures, the condition/illness leading to such a procedure is 
considered as the AE rather than the procedure itself.
The Investigators are required to grade the severity or toxicity of each AE.Investigators will reference the most recent version of the National Cancer Institute (NCI) -
Common Terminology Criteria for Adverse Events (CTCAE), a descriptive terminology that can be used for AE reporting when describing AEs.
A general grading (severity/intensity; hereafter referred to as severity) scale is provided at the 
beginning of the above referenced document, and specific event grades are also provided.
If a particular AEâ€™s severity is not specifically graded by [CONTACT_43970], the Investigator 
is to use the general NCI-CTCAE definitions of Grade [ADDRESS_46040] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N41/75The 5 general grades are:
!Grade 1 or Mild
!Grade 2 or Moderate
!Grade 3 or Severe 
!Grade 4 or Life-threatening  
!Grade [ADDRESS_46041] also be 
reported as an SAE. However, a laboratory abnormality of Grade 4, such as anemia or neutropenia,is considered serious only if the condition meets one of the serious criteria described below.
If death occurs, the primary cause of death or event leading to death should be recorded and 
reported as an SAE. â€œFatalâ€ will be recorded as th e outcome of this specific event and death will 
not be recorded as separate event. Only, if no cause of death can be reported (for example, sudden death, unexplained death), the death per se might then be reported as an SAE.
Investigators must also systematically  assess the causal relationship of AEs to the IMP using the 
following definitions. Decisive factors for the assessment of causal relationship of an AE to the 
IMP include, but may not be limited to, temporal relationship between the AE and the IMP, known side effects of the IMP, medical history, concomitant medication, course of the underlying disease, study procedures.
Unrelated: Not reasonably related to the IMP. The AE could not medically 
(pharmacologically/clinically) be attributed to the IMP under study in this clinical study protocol. A reasonable alternative explanation must be available.
Related: Reasonably related to the IMP. The AE could medically (pharmacologically/clinically) be attributed to the IMP under study in this clinical study protocol.
Abnormal Laboratory Findings and Other Abnormal Investigational Findings
Abnormal laboratory findings and other abnormal investigational findings (for example, on an 
ECG trace) should not be reported as AEs unless they are associated with clinical signs and symptoms, lead to treatment discontinuation or are considered otherwise medically important by [CONTACT_32366]. If a laboratory abnormality fulfills  these criteria, the identified medical condition 
(for example, anemia, or increased alanine aminotransferase) must be reported as the AE rather than the abnormal value itself.
Serious Adverse Events
An SAE is any untoward medical occurrence that at any dose:
!Results in death
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N42/75!Is life-threatening (Note: The term â€œlife-threateningâ€  refers to an event in which the subject is 
at risk of death at the time of the event, not an event that hypothetically might have caused death 
if it was more severe.)
!Requires inpatient hospi[INVESTIGATOR_43928]
!Results in persistent or significant disability or incapacity
!Is a congenital anomaly or birth defect
!Is otherwise considered to be medically important. (Note: Important medical events that may 
not result in death, be life-threatening, or require hospi[INVESTIGATOR_43929], based upon appropriate medical judgment, they may jeopardize the subject or may require medical or surgical intervention to prevent one of the outcomes listed above. Examples of such events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.)
For the purposes of reporting, any suspected transmission of an infectious agent via an IMP is also considered an SAE, as described in Section [IP_ADDRESS].
Events that Do Not Meet the Definition of an SAE
Elective hospi[INVESTIGATOR_43930], or to simplify study treatment or study procedures (for 
example, an overnight stay to facilitate chemotherapy and related hydration therapy application) are not considered SAEs. However, all events leading to unplanned hospi[INVESTIGATOR_43931] (for example, undesirable effects of any administered treatment) must be documented and reported as SAEs.
Events Not to Be Considered as AEs/SAEs 
Medical conditions present at the Screening visit that do not worsen in severity or frequency during 
the study are defined as Baseline Medical Conditions, and are not to be considered AEs.
Adverse Events of Special Interest 
No AEs of special interest have been defined.
[IP_ADDRESS] Methods of Recording and Assessing Adverse Events
At each study visit, the subject will be queried on changes in his or her condition. During the 
reporting period, any unfavorable changes in the subjectâ€™s condition will be recorded as AEs, whether reported by [CONTACT_9303]. 
Subjects will be educated to inform the study staff of any AE they may be experiencing, as they 
occur. While the subjects are confined to the study center, study staff will solicit responses from subjects daily for any AEs or any changes to their health in general. Furthermore, any changes in 
safety monitoring (eg, vital signs, laboratory results, etc), notable as AEs through review by [CONTACT_737]/designee, will be recorded accordingly.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N43/75Complete, accurate and consistent data on all AEs experienced for the duration of the reporting 
period (defined below) will be reported on an ongoing basis in the appropriate section of the eCRF. 
All SAEs must be additionally documented and reported using the appropriate Report Form as described in Section  [IP_ADDRESS].
It is important that each AE report include a description of the event, its duration (onset and resolution dates (and times when it is important to assess the time of AE onset relative to the recorded treatment administration time), its severity, its causal relationship with the IMP, any other potential causal factors, any treatment given or other action taken, including discontinuation of the IMP, and its outcome. In addition, serious cases should be identified and the appropriate seriousness criteria documented. 
Specific guidance can be found in the eCRF Completion Guidelines provided by [CONTACT_2024].
[IP_ADDRESS] Definition of the Adverse Event Reporting Period
The AE reporting period for safety surveillance begi ns when the subject is initially included in the 
study (date of first signature [CONTACT_43998]/) and continues until the End of Study visit. Any SAE assessed as related to the IMP must be reported whenever it occurs, irrespective of the 
time elapsed since the last administration of the IMP. 
[IP_ADDRESS] Procedure for Reporting Serious Adverse Events
Serious Adverse Events
In the event of any new SAE occurring during the reporting period, the Investigator must 
immediately (within a maximum of 24 HOURS after becoming aware of the event) inform the Sponsor or its designee using the SAE Report Form following specific completion instructions.
In exceptional circumstances, an SAE (or follow-up information) may be reported by [CONTACT_756]; 
in these cases, an SAE Report Form must be provided immediately thereafter.
Relevant pages from the eCRF may be provided in parallel (for example, medical history, 
concomitant drugs). Additional documents may be provided by [CONTACT_737], if available (for example, laboratory results, hospi[INVESTIGATOR_27450], autopsy report). In all cases, the information provided on the SAE Report Form must be consistent with the data about the event recorded in the eCRF.
The Investigator must respond to any request for follow-up information (for example, additional 
information, outcome, final evaluation, other records where needed) or to any question the Sponsor/designee may have on the AE within the same timelines as those noted above for initial reports. This is necessary to ensure prompt assessment of the event by [CONTACT_43971] (as applicable) to allow the Sponsor to meet strict regulatory timelines associated with expedited safety reporting obligations.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N44/75Requests for follow-up will usually be made via the responsible Monitor, although in exceptional 
circumstances the Global Drug Safety department may contact [CONTACT_43972].
[IP_ADDRESS] Safety Reporting to Health Authorities, Institutional Review 
Boards and Investigators
The Sponsor will send appropriate safety notifications to Health Authorities in accordance with applicable laws and regulations.
The Investigators must comply with any applicable study center-specific requirements related to 
the reporting of SAEs (particularly deaths) involving study subjects to the IRB that approved thestudy.
In accordance with ICH GCP, the Sponsor/designee will inform the Investigator of â€œfindings that 
could adversely affect the safety of subjects, impact the conduct of the study or alter the IRBâ€™s approval/favorable opi[INVESTIGATOR_43932].â€ In particular and in line with respective regulations, the Sponsor/designee will inform the Investigator of AEs that are both serious and unexpected and are considered to be related to the administered product (â€œsuspected unexpected serious adverse reactionsâ€). The Investigators should place copi[INVESTIGATOR_43933]. National regulations with regard to Safety Report notifications to Investigators will be taken into account.
When specifically required by [CONTACT_43973], the Sponsor/designee will provide the 
appropriate Safety Reports directly to the concerned lead IRB and will maintain records of these notifications. When direct reporting is not clearly defined by [CONTACT_43974]-specific regulations, the Investigator will be responsible for promptly notifying th e concerned IRB of any 
Safety Reports provided by [CONTACT_1034]/designee and of filing copi[INVESTIGATOR_43934].
For studies covered by [CONTACT_43975] 2001/20/EC, the Sponsorâ€™s responsibilities 
regarding the reporting of SAEs/suspected unexpected serious adverse reactions/Safety Issues will be carried out in accordance with that Directive and with the related Detailed Guidance documents.
[IP_ADDRESS] Monitoring of Subjects with Adverse Events
AEs are recorded and assessed continuously throughout the study (see Section [IP_ADDRESS])  and are 
assessed for final outcome at the End of Study visit. All SAEs ongoing at the End of Study visitmust be monitored and followed up by [CONTACT_43976], unless the subject is documented as â€œlost to follow-upâ€. Reasonable attempts to obtain this information must be made and documented. It is also the responsibility of the Investigator to ensure that any necessary additional therapeutic measures and follow-up procedures are performed. 
7.4.2 Pregnancy and In Utero Drug Exposure 
Only pregnancies considered by [CONTACT_43977] (for example, resulting from a drug interaction with a contraceptive medication) are considered to be AEs. However, all 
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N45/75pregnancies with an estimated conception date during the period defined in Section  [IP_ADDRESS] must 
be recorded by [CONTACT_43978]/secti on of the eCRF. The Investigator must notify the 
Sponsor/designee in an expedited manner of any pregnancy using the Pregnancy Report Form, 
which must be transmitted according to the same process as described for SAE reporting in Section [IP_ADDRESS]. 
Investigators must actively follow up, document and report on the outcome of all these pregnancies, even if the subjects are withdrawn from the study.
The Investigator must notify the Sponsor/designee of these outcomes using the Pregnancy Report 
Form. If an abnormal outcome occurs, the SAE Report Form will be used if the subject sustains an event and the Parent-Child/Fetus Adverse Event Report Form if the child/fetus sustains an event.
Any abnormal outcome must be reported in an expedited manner as described in Section  [IP_ADDRESS], 
while normal outcomes must be reported within [ADDRESS_46042] occurring during the 
course of the study, The Sponsor/designee must be notified without delay. The Investigator will 
attempt to collect pregnancy information on any female partner who becomes pregnant while her male partner is participating in the study. The Investigator will request the necessary signed informed consent from the female partner and if the consent is provided, the Investigator will record pregnancy information on the appropriate form for submission to the Sponsor. If consent is provided, follow up on the pregnancy will continue through the delivery date or termination of the pregnancy, and information regarding the pregnancy outcome and fetal/infant status at outcome (presence or absence of anomalies) will be documented.
7.4.3 Clinical Laboratory Assessments
Blood and urine samples will be collected for the following clinical laboratory tests, following the timing noted in the Schedule of Assessments for Part 1 and Part 2 (Table 1) . All samples should 
be clearly identified.  
The Sponsor should receive a list of laboratory normal ranges before shipment of the IMP. Any 
change in laboratory normal ranges during the study should be forwarded to the Sponsor or its designee.
The laboratory variables to be assessed for safety evaluations are provided in  Table 4. Unscheduled 
retest of laboratory safety tests at the discretion of the investigator are permitted during screening 
and throughout the study.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N46/75Table 4 Clinical Laboratory Evaluationsa
Biochemistry Aspartate aminotransferase
Alanine aminotransferase
Alkaline phosphataseÎ³-Glutamyltransferase
Lactate dehydrogenaseCreatine phosphokinaseBilirubin (total)Protein (total)AlbuminÎ±-1-acid glycoprotein
CholesterolTriglyceridesAmylaseLipaseUric acidSodiumPotassiumChlorideBicarbonate
Calcium
MagnesiumPhosphateCreatinineUreaGlucose
Hematology Hematocrit
HemoglobinRed blood cell count
Mean corpuscular volume
Mean corpuscular hemoglobinMean corpuscular hemoglobinconcentrationPlatelet count
White blood cell 
countWhite blood cell differentials 
and absolute counts:
Basophils
EosinophilsLymphocytesMonocytesNeutrophils
Coagulation International Normalized Ratio 
(INR)
Other Tests Hepatitis B surface antigen
Hepatitis B core antibodyHepatitis C antibody
Human immunodeficiency virus I 
and II antibodiesCotinine
Alcohol (breathalyzer)Follicle-stimulating hormone(for postmenopausal women)
Urinalysis pH
Nitrite
Protein
GlucoseKetone bodiesUrobilinogen
Bilirubin
Leukocyte esteraseBlood
Urine Microscopyb
Urine Drug ScreencCocaineAmphetaminesMethamphetamines
Opi[INVESTIGATOR_43935] (THC)
PhencyclidineOxycodone
Tricyclic antidepressants
a Subjects should fast for 8 hours prior to clinical laboratory blood sample collection.b Only if blood, protein, nitrite, or white blood cell count is positive on the dipstick.
c For all subjects, a negative cannabinoid (THC) result on drugs of abuse screening is required to participate in 
the study. If the result is positive, the Principal Investigator [INVESTIGATOR_43918]. For subjects with 
hepatic impairment, a positive cannabinoid (THC) result on drugs of abuse screening will not be exclusionary 
(at Screening or Day -1) if the hepatic-impaired subject uses cannabinoids on medical recommendation. In subjects with hepatic impairment, positive test for drugs used on medical recommendation will be not 
exclusionary.
The total blood volume to be drawn from each subject for planned assessments during the study 
will not exceed the volume of a standard donation (approximately 450 mL) and will be specified 
in the laboratory manual.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N47/757.4.4 Vital Signs, Physical Examinations, and Other Assessments
[IP_ADDRESS] Vital Signs
Vital signs, including oral temperature, systolic and diastolic blood pressure, and pulse rate will 
be assessed as per the timepoints specified in the Schedule of Assessments for Part 1 and Part 2(Table 1) .
A semi-automated pulse rate and blood pressure recording device with an appropriate cuff sizewill be utilized. The pulse rate and blood pressure will be measured after [ADDRESS_46043] in the semi-supi[INVESTIGATOR_2547] (supi[INVESTIGATOR_43936] 12-lead ECG assessment) with the subjectâ€™s arm unconstrained by [CONTACT_43979]. The blood pressure should be assessed on the same arm for each subject throughout the study.
[IP_ADDRESS] Physical Examination
Complete physical examinations will be performed at the timepoints specified in the Schedule of 
Assessments for Part 1 and Part 2 (Table 1) and will include an assessment of: general appearance, 
skin, head and neck, lymph nodes, thyroid, abdomen, and musculoskeletal, cardiovascular, respi[INVESTIGATOR_696], and neurological systems.
Body weight will be measured at Screening and at Day -1. Height will be measured at Screening 
only.All clinically significant abnormalities occurring before signature [CONTACT_43999]/or disease history section of the eCRF; all abnormalitiesoccurring or worsening after the subject signed the Informed Consent Form should be recorded in the AE section of the eCRF.
[IP_ADDRESS] Electrocardiograms
Standard 12-lead ECGs will be performed at the timepoints specified in the Schedule of Assessments for Part 1 and Part 2 (Table 1) after [ADDRESS_46044] in th e supi[INVESTIGATOR_2547]. Only the 
overall evaluation (normal/abnormal) will be recorded in the eCRF, and if abnormal, the specific 
abnormality will be recorded. Abnormal evaluations will be judged as clinically significant or not clinically significant by [CONTACT_737]. The ECG recordings must be performed before PK sampling timepoints on days where both assessments are performed.
7.5 Pharmacokinetics
7.5.1 Body Fluids
Blood samples for the PK evaluation of tepotinib and its metabolites (MSC2571109 and MSC2571107) in plasma will be collected at the timepoints specified in the Schedule of Assessments for Part 1 and Part 2 (Table 1) . The exact date and time of sample collection will be 
recorded in the eCRF. Samples not collected at the exact timepoint are not to be considered 
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N48/75protocol deviations as long as the actual collecti on date and time is recorded. Every effort should 
be made to collect samples at the appropriate timepoint.
Details of the sample collection, blood volume, labeling, storage and shipment requirements will 
be provided in a separate manual of operations or laboratory manual.
The PK sampling is planned differently for health y subjects than for hepatic impaired subjects as 
a different half-life is expected. As the majority of healthy subjects do not have measureable 
concentrations after Day 15, PK sampling until Day [ADDRESS_46045], an additional sampling time of 1 week (up to Day 22) is considered to be  sufficient. The SMC may decide on a different 
sampling scheme for Part 2.
All sample analyses will be performed using a validated method measuring parent drug and 
metabolites.
The free fraction of tepotinib will be determined to assess a potential effect of low serum albumin 
concentration which might result in an increased free fraction of tepotinib in subjects with hepatic impairment. 
7.5.2 Pharmacokinetic Calculations
The PK parameters (see Table 5)  of tepotinib and its metabolites MSC2571109 and MSC2571107, 
if applicable, will be evaluated. Noncompartmental computation of PK parameters will be performed using the software PhoenixÂ® WinNonlinÂ® 6.4 or higher (Certara, L.P., Princeton, NJ, [LOCATION_003], SASÂ® System (Version 9.4 or later; SAS Institute, Cary, NC, [LOCATION_003]) or equivalent software.Individual PK parameters will be calculated using actual sample collection times. The predose sample time will be considered as if it had been taken simultaneously with the IMP administration.
Pharmacokinetic variables will be evaluated and listed for all subjects who provide sufficient concentration-time data.
If AUC
extra% is greater than 20%, Î»zand all derived parameters should be flagged as invalid.
Plasma concentrations BLQ before the last quantifiable data point will be taken as zero for 
calculating the AUC (ie, embedded BLQ values set to zero). Plasma concentrations BLQ after the last quantifiable data point will not be considered for the determination of Î»
Z.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N49/75Table 5 Definition of Pharmacokinetic Parameters
Tepotinib and its Metabolites
Symbol Definition
AUC 0-t Area under the plasma concentration-time curve (AUC) from time zero to the 
last sampling time at which the concentration is at or above LLOQ, calculated according to the mixed log linear trapezoidal rule (ie, linear up/log down)
AUC 0-âˆž Area under the plasma concentration-time curve from time zero to infinity, calculated as AUC
0-t+ AUC extra% , according to the mixed log linear 
trapezoidal rule (ie, linear up/log down). AUC extra% represents the extrapolated 
part of AUC 0-âˆž calculated by C lastcalc /Î»Z, where C lastcalc is the calculated plasma 
concentration at the last sampling timepoint at which the measured plasma concentration is at or above LLOQ
Cmax Maximum plasma concentration observed
tmax Time to reach the maximum plasma concentration
t1/2 Apparent terminal half-life, calculated as ln2/ Î»Z
Î»Z Apparent terminal rate constant determined from the terminal slope of the 
logâˆ€transformed plasma concentration curve using linear regression on 
terminal data points of the curve
CL/f Total body clearance of drug from plasma following oral administration, 
calculated as Dose/AUC 0-âˆž(for tepotinib only)
VZ/f Apparent volume of distribution during the terminal phase following 
extravascular administration, calculated as Dose/(AUC 0-âˆž*Î»z)
AUC extra% Area under the plasma concentration-time curve extrapolated from time t to 
infinity as a percentage of AUC 0-âˆž
MRAUC 0-âˆž Metabolite (MSC2571109 or MSC2571107) AUC 0-âˆžto tepotinib AUC 0-âˆž ratio
MRC max Metabolite (MSC2571109 or MSC2571107) C maxto tepotinib C max ratio
7.6 Biomarkers
No biomarker assessments are planned.
7.7 Other Assessments
No other assessments are planned.
8 Statistics
Details of the statistical analyses will be described in a separate statistical analysis plan.
8.1 Sample Size
Pharmacokinetic studies including subjects with impaired hepatic function are usually exploratory by [CONTACT_6073]. Considering the CVs for the primary endpoints AUC
0-tand C maxof tepotinib, 20.4% 
and 22.8% respectively (Study EMR200095-007), 6 evaluable subjects per group will provide 80% power for detecting a group difference of 44% (AUC
0-t) and 50% (C max), which is considered 
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N50/75sufficient to meet the study objectives having the therapeutic window of tepotinib in mind. The 
significance level was set to 0.05 two-sided.
Therefore, 18 subjects (3 groups x 6 subjects) should be included in Part 1 and 6 subjects in Part 2. 
Drop-outs will be replaced only if they cannot provide an evaluable PK profile.
8.2 Randomization
Not applicable.
8.3 Endpoints
8.3.1 Primary Endpoints
!PK profile of tepotinib (plasma) in terms of AUC 0-t, AUC 0-âˆž, and C maxat Day 1 to Day 15 
(healthy subjects) or Day 22 (hepatic impaired subjects) calculated by [CONTACT_43951].
8.3.2 Secondary Endpoints
!PK profile of tepotinib (plasma) in terms of t max, t1/2, CL/f, V Z/f, AUC extra% at Day 1 to Day 15 
(healthy subjects) or Day 22 (hepatic impaired subjects) calculated by [CONTACT_43950]2571109 and MSC2571107 (plasma) in 
terms of AUC
0-t, AUC 0-âˆž, Cmax, tmax, t1/2, AUC extra% at Day 1 to Day 15 (healthy subjects) or 
Day 22 (hepatic impaired subjects) calculated by [CONTACT_43951], and MRAUC 0-âˆž
and MRC max
!Occurrence of TEAEs, changes from baseline in laboratory safety tests, 12-lead ECG
morphology and time intervals (PR, QRS, RR, QT and QTcF), and vital signs.
8.3.[ADDRESS_46046] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N51/75Pharmacokinetic Analysis Set
The Pharmacokinetic Analysis Set will include all subjects who receive a single dose of the study
treatment and have at least 1 postdose PK measurement without important protocol deviations/violations or events (such as vomiting within 2 times the median t
max, after dosing) that 
may affect the PK. All PK analyses will be based on this analysis set.
8.5 Description of Statistical Analyses
8.5.1 General Considerations
Section  10.6.1 describes the process for performing analyses and reporting of results.
Statistical analysis will be performed using the computer program package SAS System (Version 9.4 or later; SAS Institute, Cary North Carolina, US). 
Details on the statistical analysis will be presented in the statistical analysis plan that will be 
finalized prior to database lock.
The statistical analyses will not be  started until all data for Part [ADDRESS_46047] been completed. Part 2 of the 
study is optional, and if conducted, the results will be provided in an addendum to the CSR.
All data recorded during the study will be presented in individual data listings performed on the 
Safety Analysis Set, as appropriate.
All data will be evaluated as observed; no imputation method for missing values will be used.Plasma concentration data will be summarized descriptively for all PK analytes (tepotinib and its 
metabolites) by [CONTACT_43980]. Any values BLQ will be taken as zero for descriptive statistics.
8.5.2 Analysis of Primary Endpoints
As the primary analysis, an analysis of variance (ANOVA) model including hepatic function group as a fixed effect will be applied to log-transformed tepotinib PK parameters AUC
0-t, AUC 0-âˆž,a n d  
Cmaxof the hepatic impairment groups (Child-Pugh class A and Child-Pugh class B) and matched 
control group (healthy subjects). Di fferences between the hepatic impairment groups and matched 
control will be estimated together with their 90% CIs on the log scale. Point estimates and CIs will 
be back-transformed to the original scale for presentation. 
Additionally, a generalized linear model including hepatic function group and sex (gender) as fixed 
effects, age and weight as covariates, will be applied to the same primary PK parameters. A further covariate log(dose) will be introduced, when/if Part [ADDRESS_46048] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N52/75All endpoints will be descriptively analyzed using summary statistics by [CONTACT_42469]. 
Graphical displays will be presented, where appropriate.
8.5.3 Analysis of Secondary Endpoints
For the secondary PK parameters AUC 0-t, AUC 0-âˆž, and C maxof the tepotinib metabolites, the same 
analyses as defined for the primary endpoints will be performed.
In a further analysis, the subjects with liver impairment will be evaluated according to the 
Albumin-Bilirubin (ALBI) score and the Organ Dysfunction Working Group (ODWG) classification (12,13) . Further details of the statistical analyses will be described in a statistical 
analysis plan. 
8.5.[ADDRESS_46049] up-to-date version 
of the NCI-CTCAE toxicity grades. 
Observed and change-from-baseline laboratory values will be summarized by [CONTACT_43981], by [CONTACT_43982]/outliers, as appropriate. 
Clinically significant, abnormal findings from the physical examination are to be reported as AEs. 
Separate summaries of the physical examination will not be provided. Vital signs and 12-lead ECG 
data will be summarized for observed and change-from-baseline values by [CONTACT_43983]. Clinically noteworthy 12-lead ECG findings for individual subjects will be listed and summarized as appropriate.
8.6 Interim and Additional Planned Analyses
An SMC may be established to evaluate th e safety and PK results of Part 1 and provide 
recommendations on the tepotinib dose and population to be enrolled in Part 2 if the overall development program of tepotinib decides to use higher doses than 500 mg (up to 1000 mg) in the Phase [ADDRESS_46050] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N53/75Declaration of Helsinki, ICH GCP, and any other applicable regulations. The Investigators must 
ensure that only subjects who have given informed consent are included in the study.
According to [LOCATION_002] Code of Federal Regulations Part 54.2 (e), for studies conducted in any 
country that could result in a product submission to the [LOCATION_002] FDA for marketing approval and could contribute significantly to the demonstration of efficacy and safety of an IMP (which are considered â€œcovered clinical trialsâ€ by [CONTACT_1622] ), the Investigator and all subinvestigators are 
obliged to disclose any financial interest which they, their spouses or their dependent children may have in the Sponsor or the Sponsorâ€™s product under study. This information is required during the study and for [ADDRESS_46051] by [CONTACT_43984] (if local regulations permit) before informed consent is obtained. 
A subject information sheet must be prepared in the local language in accordance with ICH GCP
and will be provided by [CONTACT_43985]. In addition to providing this written information to a potential subject, the Investigator or a designate will inform the subject verbally of all pertinent aspects of the study, using language chosen so that the information can be fully and readily understood by [CONTACT_43986]. The subject will be given sufficient time to read the information and the opportunity to ask questions and to request additional information and clarification.
If permitted by [CONTACT_2091], a person other than the Investigator may inform the subject 
about the study and sign the Informed Consent Form, as above.
After the information is provided by [CONTACT_737], the Informed Consent Form must be signed 
and dated by [CONTACT_43987]. 
The signed and dated declaration of informed consent will remain at the Investigatorâ€™s study 
center, and must be safely archived so that the forms can be retrieved at any time for monitoring, auditing and inspection purposes. A copy of the signed and dated information and Informed Consent Form should be provided to the subject prior to participation.
Whenever important new information becomes available that may be relevant to informed consent, 
the Investigator will revise the subject information sheet and any other written information to beprovided to the subjects and submit them to the IRB for review and opi[INVESTIGATOR_1649]. Using the approved 
revised subject information sheet and other written information, The Investigator will explain the changes to the previous version to each study subject and obtain new written consent for continued participation in the study. The subject will be given sufficient time to read the information and the opportunity to ask questions and to request additional information and clarification about the changes.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N54/759.[ADDRESS_46052]â€™s identifier in the study as well as in the clinical 
study database. All subject data collected in the study will be stored under the appropriate subjectnumber. Only the Investigator will be able to link study data to an individual subject via an identification list kept at the study center. For each subject, original medical data will be accessible for the purposes of source data verification by [CONTACT_35717], audits and regulatory inspections, but patient confidentiality will be strictly maintained.
Data protection and privacy regulations will be observed in capturing, forwarding, processing, and 
storing subject data. Subjects will be informed accordingly, and will be requested to give their consent on data handling procedures in accordance with national regulations.
9.[ADDRESS_46053]
Prior to commencement of the study at a given cen ter, this clinical study protocol will be submitted 
together with its associated documents (Subject Information, Informed Consent Form, Investigatorâ€™s Brochure, subject card) to the responsible IRB for its fa vorable opi[INVESTIGATOR_43937], 
which will be filed in the Investigator Site File . A copy will be filed in the Sponsor Trial Master 
File at the CRO.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N55/75The IRB will be asked to document the date of the meeting at which the favorable opi[INVESTIGATOR_43938]. Written evidence of favorable opi[INVESTIGATOR_43939], the clinical study protocol version and the 
Subject Information and Informed Consent Form version reviewed should be provided. Where possible, copi[INVESTIGATOR_43940].
Amendments to this clinical study protocol will als o be submitted to the concerned IRB, before 
implementation of substantial changes (see Section 10.5) . Relevant safety information will be 
submitted to the IRB during the course of the st udy in accordance with national regulations and 
requirements.
9.7 Health Authorities
The clinical study protocol and any applicable documentation (ie, Investigational Medicinal 
Product Dossier, Subject Information and Informed Consent Form) will be submitted or notified to the Health Authorities in accordance with all local and national regulations for each study center.
[ADDRESS_46054] names.
The data will be entered into a validated database. The Sponsor or its designee will be responsible 
for data processing, in accordance with the Sponsorâ€™s data management procedures. Database lock will occur once quality control and quality assurance procedures have been completed. PDF files of the eCRFs will be provided to the Investigators at the completion of the study.
The eCRFs are essential study documents and must be suitable for regulatory inspections and 
submissions.
10.[ADDRESS_46055] keep a file (medical file, original medical records) on paper or electronically for every subject in the study. It must be possible to identify each subject by [CONTACT_43988]. This file will contain the demographic and medical information for the subject listed below and should be as complete as possible:
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N56/75!Subjectâ€™s full name, date of birth, sex (gender), height, weight
!Medical history and concomitant diseases
!Prior and concomitant therapi[INVESTIGATOR_014] (including changes during the study)
!Study identification, that is, the Sponsor study number for this clinical study, and subject 
number
!Dates for entry into the study (informed consent) and visits to the study center
!Any medical examinations and clinical findings predefined in this clinical study protocol
!All AEs
!Date that the subject left the study including any reason for early study discontinuation or 
withdrawal from IMP (if applicable).
All documents containing source data must be filed, including, but not limited to computed 
tomography or magnetic resonance imaging scan images, ECG recordings, and laboratory results.Such documents must bear the subject number and the date of the procedure. If possible, thisinformation should be printed by [CONTACT_43989]. As necessary, medical evaluation of such records should be performed; all evaluations should be documented, signed, and dated by [CONTACT_737].
The Monitor will be trained to use the electronic database / eCRF and will have read-only access 
to the study data in the eCRF for source data verification. Data reviewed can be signed off and queries issued directly in the eCRF.
10.[ADDRESS_46056] 15 years (or longer, per local requirements or as otherwise notified by [CONTACT_1034]) after the end of the study. The documents to be ar chived include the Subject Identification List and 
the signed subject Informed Consent Forms. If archiving of the Investigator Site File is no longer possible at the study center, the Investigator must notify the Sponsor/designee.
All original subject files (medical records) must be stored at the study center for the longest 
possible time permitted by [CONTACT_1729], and/or as per ICH GCP guidelines, whichever is longer. In any case, the Investigator should ensure that no destruction of medical records is performed without the written approval of the Sponsor.
10.[ADDRESS_46057] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N57/75The clinical study protocol, each step of the data capture procedure, and the handling of the data, 
including the final CSR, will be subject to i ndependent Quality Assurance activities. Audits may 
be conducted at any time during or after the study to ensure the validity and integrity of the studydata. Representatives of the Quality Assurance unit from the Sponsor or a designated organization, as well as Health Authorities, must be permitted to access all study documents and other materials at the study center, including the Investigator Site File, the completed eCRFs, all IMP and IMP accountability records, and the original medical records or files for each subject.
10.5 Changes to the Clinical Study Protocol
Changes to the clinical study protocol will be documented in writing. Substantive amendments will usually require submission to the Health Authorities and to the relevant IRB for approval or favorable opi[INVESTIGATOR_1649]. In such cases, the amendment will be implemented only after approval or favorable opi[INVESTIGATOR_43941].
Minor (nonsubstantial) protocol amendments, including administrative changes, will be filed by 
[CONTACT_43990]. They will be  submitted to the relevant IRB or to Health 
Authorities only where requested by [CONTACT_43991]. Any amendment that could affect the subjectâ€™s agreement to participate in the study requires additional informed consent prior to implementation following the process as described in Section  9.2.
10.6 Clinical Study Report and Publication Policy
10.6.1 Clinical Study Report
After completion of Part 1 of the study, the final CSR will be written by [CONTACT_43992] E3. Part 2 of the study is optional, and if conducted, the results will be provided in an addendum to the CSR.
10.6.2 Publication
The Investigator will inform the Sponsor in advance about any plans to publish or present data from the study. Any publications and presentations of the results (abstracts in journals or newspapers, oral presentations, etc), either in whole or in part, by [CONTACT_43993]. The Sponsor will not suppress publication, but maintains the right to delay publication in order to protect intellectual property rights.
11 References Cited in the Text
1. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev 
Mol Cell Biol . 2003;4(12):915-25
2. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting 
oncogene addiction and expedience. Nat Rev Drug Discov . 2008;7(6):504-16.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N58/753. Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met 
signaling pathway in cancer. Clin Cancer Res . 2009;15(7):2207-14.
4. EMA, ICH Guideline M3(R2) on Non-Clinical Safety Studies for the Conduct of Human 
Clinical Trials and Marketing Authorization for Pharmaceuticals. EMA/CPMP/ICH/286/1995. 
December 2009.
5. FDA, Guidance for Industry, Drug Interaction Studies - Study Design, Data Analysis, 
Implications for Dosing, and Labeling, Recommendations. February 2012.
6. Liu X, Newton RC, Scherle PA. Development of c-MET pathway inhibitors. Expert Opin 
Investig Drugs . 2011;20(9):1225-41.
7. Spi[INVESTIGATOR_43942], Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized 
phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol. 2011;29(suppl; abstr 7505).
8. Oliner KS, Tang R, Abraham A, et al. Evaluation of MET pathway biomarkers in a Phase II 
study of rilotumumab (R, AMG 102) or placebo (P) in combination with epi[INVESTIGATOR_14962], cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol . 2012;30(suppl; abstr 4005).
9. U.S. Food and Drug Administration. Guidance for Industry Pharmacokinetics in Patients with 
Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), May 2003.
10. Sherman M. Hepatocellular carcinoma: epi[INVESTIGATOR_623], surveillance, and diagnosis. Semin 
Liver Dis. 2010;30:3-16.
11. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet . 2012;379(9822):1245-55.
12. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with 
hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol . 
2015; 33(6): 550-558.
13. LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al. Pharmacokinetics and safety of 
bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: Phase 1 NCI Organ Dysfunction Working Group study NCI-6432. Clin Cancer Res . 2012;
18(10), doi:10.1158/1078-0432.CCR-11-2873.
14. Pugh RN, Murray-Lyon IM, Dawson JL, et. al. Transection of the oesophagus for bleeding 
oesophageal varices. Br J Surg. 1973; 60:646-649. 
15. Child CG, Turcotte JG. The Liver and Portal Hypertension. Philadelphia, WB Saunders Co. 
1964. NLMN: [ADDRESS_46058] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N59/7516. Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by [CONTACT_43994]. 
NEJM . 1966; 274:473-481.  
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N60/[ADDRESS_46059] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N61/75Appendix I: Contraceptive Guidance and Woman of Childbearing Potential
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpi[INVESTIGATOR_1656], and bilateral oophorectomy.
Women in the following categories are not considered WOCBP
1. Premenopausal female with 1 of the following:
!Documented hysterectomy
!Documented bilateral salpi[INVESTIGATOR_1656]
!Documented bilateral oophorectomy
Note:  Documentation can come from the study center personnelâ€™s: review of participantâ€™s 
medical records, medical examination, or medical history interview.
2. Premenarchal 
3. Postmenopausal female
!Females who are postmenopausal (age-related amenorrhea â‰¥12 consecutive months and 
increased follicle-stimulating hormone [FSH] > 40 mIU/mL), or who have undergone 
hysterectomy or bilateral oophorectomy are exempt from pregnancy testing. If necessary to confirm postmenopausal status, an FSH will be drawn at Screening.
!Females on HRT and whose menopausal status is in doubt will be required to use one of the 
non-hormonal highly effective contraception methods if they wish to continue their HRT 
during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N62/75Contraceptive Guidance
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctlya. 
!Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulationb
!oral 
!intravaginal 
!transdermal 
!Progestogen-only hormonal contraception associated with inhibition of ovulationb
!oral 
!injectable
Highly Effective Methods That Are User Independent 
!Implantable progestogen-only hormonal contraception associated with inhibition of ovulationb
!Intrauterine device (IUD)
!Intrauterine hormone-releasing system (IUS)
!bilateral tubal occlusion
!Vasectomized partner 
(A vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. 
!Sexual abstinence 
(Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.) 
NOTES: 
a) Typi[INVESTIGATOR_35818]. Use should be consistent with 
local regulations regarding the use of contraceptive methods for participants participating in clinical studies. 
b) Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of 
the contraceptive method. In this case two highly effective methods of contraception should be utilized during the treatment period and for at least [ADDRESS_46060] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N63/75Appendix II: Signature [CONTACT_44000] m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
T e p oti ni b ( M S C 2 1 5 6 1 1 9 J) T e p oti ni b H e p ati c I m p ai r m e nt T ri al 
M S [ADDRESS_46061] u d y Title: O p e n- L a b el , P ar all el- Gr o u p P h as e St u d y t o 
I n v esti g at e t h e Eff e ct of V ari o us D e gr e es of H e p ati c 
I m p air m e nt o n t h e P h ar m a c o ki n eti cs , S af et y a n d 
T ol er a bilit y of t h e c- M et Ki n as e I n hi bit or T e p oti ni b 
I N D N u m b e r: [ADDRESS_46062] u d y P r ot o c ol  D at e I 2 4 A pril 2 0 1 8 I V ersi o n 2. 0 
V e rsi o n: 
P r ot o c ol L e a d: 
I a p pr o v e t h e d esi g n of t h e cli ni c al st u d y: 
Si g n at ur e D at e of Si g n at ur e 
N a m e , a c a d e mi c d e gr e e:  
F u n cti o n I Titl e:  
I nstit uti o n: M er c k K G a A 
A d dr ess: Fr a n kf urt er Str ass e [ADDRESS_46063] a dt , G er m a n y 
T el e p h o n e n u m b er :  
F a x n u m b er:  
E- m ail a d dr ess:  
D o c u m e nt N o. [ADDRESS_46064] N o. 0 9 0 0 ba b e8 0f 6 5 5e 0 C O N FI D E NTIA L 
I  N F  O  R M ATI O N 6 4 / 7 5 PI [INVESTIGATOR_43943]
T e p oti ni b ( M S C 2l 5 6 1 1 9 J) T e p oti ni b H e p ati c I m p ai r m e nt T ri al 
M S [ADDRESS_46065] u d y pr ot o c ol, a n y a p pr o ve d 
pr ot o c ol a m e n d m e nts, I nt er n ati o n al C o u n cil f or H ar m o ni z ati o n G o o d Cli ni c al Pr a cti c e ( T o pic E 6) 
a n d all a p pli c a bl e H e alt h A ut h orit y r e q uir e m e nts a n d n ati o n al la ws. 
I als o affir m t h at I u n d erst a n d t h at H e alt h A ut h oriti es m a y r e q uir e t he S p o ns ors of cli ni c al st u di es 
t o o bt ai n a n d s u p pl y d et ails a b o ut o w n ers hi p i nt er ests i n t h e S p o ns or or I n v esti g ati o n al Me dici nal 
Pr o d u ct a n d a n y ot h er fi n a n ci al ti es wit h t he S p o ns or. T h e S p o ns or will use a n y s u c h i nf or mati o n 
s ol el y f or t h e p ur p os e of c o m pl yi n g wit h t h e r e g ul at or y r e q uir e m e nts. I t h er ef or e a gr e e t o s u p pl y 
t h e S p o ns or wit h a n y n e c ess ar y i nf or m ati o n r e g ar di n g o w n ers hi p i nt er est a n d fi na ncial ti es 
i n cl u di n g t h os e of m y s p o use a n d d e p e n d e nt c hil dr e n, a n d t o pr o vi d e u p d at es as n e c ess ar y t o m e et 
H e alt h A ut h orit y r e q uir e m e nts.  
Si g n at ur e 
N a m e, a c a d e mi c de gree: 
F u n cti o n I Titl e: 
I nstit uti o n: 
A d dr ess: 
T el e p h o n e n u m b er: 
F a x n u m b er: 
E- m ail a d dr ess:  
Pri n ci p al I n v esti g at or D at e of Si g n at ur e 
Orl a n d o Cli ni c al R es e ar c h C e nt er 
[ADDRESS_46066] N o. 0 9 0 0 b a b e 8 0f 6 5 5 e 0 C O N FI D E N TI A L 
I N F O R M A TI O N 6 5 1 7 5 PI[INVESTIGATOR_43944]
T c p oti ni h ( M S C 2 1 5 6 1 1 9. 1) T c p oti ni b H e p ati c I m p air m e nt Tri al 
M S [ADDRESS_46067] of V ari o us D e gr e es of H e p ati c 
I m p air m e nt o n t he P h ar m a c o ki n eti cs, S al' et y a n d 
T ol er a bilit y of t h e c- M et Ki n as e I n hi bit or T e p oti ni b 
1 0 6 1 0 3 
2 4 A pril 2 0 1 8 / V ersi o n 2. [ADDRESS_46068] u d y pr ot o c ol. a n y a p pr o v e d 
pr ot o c ol a m e n d m e nts, I nt er n ati o n al C o u n cil t or H ar m o ni z ati o n G o o d Cli ni c al Pr a cti c e ( T o pi c E 6) 
all a p pli c a bl e H e alt h A ut h orit y r e q uir e m e nts a n d n ati o n al la ws. , .. 
I als o affir m t h at I u n d erst a n d t h at H e alt h A ut h oriti es ma y r e q uir e t he S p o ns ors of cli ni c al st u di es 
t o o bt ai n a n d s u p pl y d et ails a b o ut o w n ers hi p i nt er ests i n t h e S p o ns or or I n v esti g ati o n al M e di ci n al 
Pr o d u ct a n d a n y ot h er fi n a n ci al ti es wit h t h e S p o ns or. T h e S p o ns or will us e a n y s u c h i nf or m ati o n 
s ol el y f or t he p ur p os e of c o m pl yi n g wit h t h e r e g ul at or y r e q uir e m e nts. I t h er ef or e a gr e e t o s u p pl y 
t he S p o ns or wit h a n y n e c ess aiJ i nf or m ati o n r e g ar di n g o w n ers hi p i nt er est a n d fi n a n ci al ti es 
i n cl u di n g t h os e of m y s p o us e a n d d e p e n d e nt c hil dr e n. a n d t o pr o vi d e u p d at es as n e c ess ar y t o m e et 
Si g n at ur e D at e of Si g n at ur e 
N a m e. a c a d e mi c d e gr e e:  
F u n cti o n I Titl e: Pri n ci p al I n v esti g at or 
I nstit uti o n: Q P S M R A. L L C 
A d dr ess: 6 2 8 0 S u ns et Dri v e, S uit e 6 0 0 
Mi a mi. F L., 3 3 1 4 3. U S A 
T el e p h o n e n u m b er:  
F a x n u m b er:  
E- mail a d dr ess:  
O oc u mc nl N o. 0 9 0 0 ba b d! O G 7 4 5 2 vi. O 
O hjccl N o. 0 9 0 0 ha bcl!fllr. 5 5cll C O NI Â·I D L N I 1/\ L 
I Nf O R M A TI O N ..... PI
[INVESTIGATOR_43945] p oti ni b ( M S C 2 1 5 6 1 1 9 J) Te p oti ni b  He p atic I m p air me nt Tri al
M S 2 0 0 0 9 5- 0 0 2 8
C O N F I D E N T I A L
I N F O R M A T I O N6 7/ 7 5S p o ns or Res p o nsi ble Pers o ns n ot N a me d o n t he C o ver P a ge
Na me, aca de mic de gree:
F u ncti o n / Title:I nstit uti o n: E M D Ser o n o, I nc.
A d dress: 4 5 A Mi d dlese x T ur n pi [INVESTIGATOR_2531], Billerica, M A 0 1 8 2 1, U S A
Tele p h o ne n u m ber:Fa x n u m ber: -
E- mail a d dress:
Na me, aca de mic de gree: , 
F u ncti o n / Title:
I nstit uti o n: Merc k K Ga A
A d dress: Fra n kf urter Strasse 2 5 0, 6 4 2 9 3 Dar msta dt, Ger ma n y
Tele p h o ne n u m ber:Fa x n u m ber:E- mail a d dress:
Na me, aca de mic de gree:
F u ncti o n / Title:I nstit uti o n: Merc k K Ga A
A d dress: Fra n kf urter Strasse 2 5 0, 6 4 2 9 3 Dar msta dt, Ger ma n y
Tele p h o ne n u m ber:Fa x n u m ber: -
E- mail a d dress:
D o c u me nt N o.  
O bject N o.  PI
[INVESTIGATOR_43946] (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N68/75Appendix III:Protocol Amendments and List of Changes
Table of Amendments
Amendment 
NumberSubstantial
(Y/N)Date Region or Country Included in the 
current document
(Y/N)
[ADDRESS_46069] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N69/75Amendment #1
Effective date: [ADDRESS_46070] No .   EDEHIY
EDEHIH
Te p oti ni b ( M S C 2 1 5 6 1 1 9 J) Te p oti ni b  He p atic I m p air me nt Tri al
M S 2 0 0 0 9 5- 0 0 2 8
C O N F I D E N T I A L
I N F O R M A T I O N7 0/ 7 5C o m p aris o n wit h Cli nic al Tri al Pr ot oc ol Versi o n 1. 0, 1 5  M arc h 2 0 1 7
C h a n g e S e cti o n P a g e Pr e vi o u s W or di n g N e w W or di n g
C h a n g e i n 
cli ni c al sit e s
a n d S p o n s or 
M e di c al 
R e s p o n si bl e.Titl e p a g e, 
s y n o p si s, 
S e cti o n 2,A p p e n di x II1, 1 8, 6 4, 6 5 D a Vit a Cli ni c al R e s e ar c h â€“
Mi n n e a p oli s
8 2 5 S o ut h 8t h Str e et, S uit e 3 0 0Mi n n e a p oli s, M N 5 5 4 0 4, U S AP h o n e: E m ail: 
D a Vit a Cli ni c al R e s e ar c h â€“
D e n v er
St. A nt h o n y' s M e di c al Pl a z a [ADDRESS_46071] a c e, S uit e 
3 0 0
L a k e w o o d, C O 8 0 2 2 8, U S AP h o n e: E m ail:
M e di c al R e s p o n si bl e:
M er c k K G a A, Fr a n kf urt er 
Str a s s e [ADDRESS_46072] a dt, G er m a n y
P h o n e: 
M o bil e: 
E m ail: D a Vit a Cli ni c al R e s e ar c h â€“  Mi n n e a p oli s
8 2 5 S o ut h 8t h Str e et, S uit e 3 0 0
Mi n n e a p oli s, M N 5 5 4 0 4, U S AP h o n e: 
E m ail: 
D a Vit a Cli ni c al R e s e ar c h â€“  D e n v er
St. A nt h o n y' s M e di c al Pl a z a [ADDRESS_46073] a c e, S uit e 3 0 0
L a k e w o o d, C O 8 0 2 2 8, U S A
P h o n e: 
E m ail:
Orl a n d o Cli ni c al R e s e ar c h C e nt er
5 0 5 5 S. Or a n g e A v e
Orl a n d o, F L 3 2 8 0 9, U S A
P h o n e:  
E m ail:  
Q P S M R A, L L C6 2 8 0 S u n s et Dri v e, S uit e 6 0 0Mi a mi, F L., 3 3 1 4 3, U S AP h o n e:E m ail:
M e di c al R e s p o n si bl e:
 
 
M er c k K G a A, Fr a n kf urt er Str a s s e [ADDRESS_46074] a dt, G er m a n y
P h o n e:  
M o bil e:  
E m ail: 
D o c u me nt N o.  
O bject N o.  PI[INVESTIGATOR_43947] (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N71/75Change Section Page Previous Wording New Wording
Matching 
criteria was 
changed so 
that matches 
can be identified before the 
last moderate 
hepatic impairment subject is identified.Synopsis 11 Part 1 will include subjects with 
hepatic impairment (Child-Pugh class A [6 subjects] and Child-
Pugh class B [6 subjects]) and a 
control group (6 healthy subjects matched to 6 subjects with Child-Pugh class B). All 
subjects will receive a single 
dose of 500 mg tepotinib.Part 1 will include subjects with hepatic 
impairment (Child-Pugh class A [6 
subjects] and Child-Pugh class B [6 
subjects]) and a control group (6 
healthy subjects matched 1:1to [ADDRESS_46075] to age Â± 10 years, weight 
Â± 10 kg, and same gender ). All 
subjects will receive a single dose of 
[ADDRESS_46076] visits 
were clarified.Table 1 15 - Visit number was added.
Schedule of 
assessments 
clarifiedTable 1 16 â€œxâ€ was marked for "subject 
confinement" at EOS for healthy subjectsâ€œxâ€ marked for "subject confinement" at 
EOS for healthy subjects was
removed.
Row for Visit number was added.
Day 15 visit 
column was 
renamed.Table 1 Day 15 
visit column16 End of Study for Healthy 
SubjectsEnd of Study for Healthy Subjects /
Treatment visit for Hepatic Impaired Subjects
Drug 
screening 
instructions 
were clarified.Table 1, 
footnote j16 For healthy subjects, a positive 
cannabinoid (THC) result on drugs of abuse screening may be repeated and if negative on 
repeat, the subject will be 
allowed to participate in the 
study.  For healthy all subjects, a positive
negative cannabinoid (THC) result on 
drugs of abuse screening may be 
repeated and if negative on repeat, the 
subject will be allowed is required to 
participate in the study. If the result is 
positive, the Principal Investigator 
[INVESTIGATOR_43918]. 
New footnote 
added to clarify TFF 
sampling in Schedule of assessments 
and following 
footnotes were 
renumbered.Table 1, 
footnote f17 The Tepotinib Free Fraction (TFF) 
sample will not be drawn separately; TFF will be analyzed from the PK 
back up sample.
CRO name 
[CONTACT_44001]2 Sponsor, 
Investigators and Study 
Administrative 
Structure18 The Sponsor will partner with 
QuintilesIMS, a contract 
research organization (CRO), to 
conduct the clinical part of the study including study set-up, coordination, monitoring, data capture, data management, 
statistical analysis, and CSR 
preparation.The Sponsor will partner with 
QuintilesIMS, a contract research 
organization (CRO), to conduct the 
clinical part of the study including study set-up, coordination, monitoring, data capture, data management, statistical 
analysis, and CSR preparation.
"LabCorp" 
and â€œNuvisanâ€ 
names were
removed 2 Sponsor, 
Investigators 
and Study Administrative Structure18 LabCorp will serve as the 
central laboratory for clinical laboratory analysis. Nuvisan will 
be responsible for analysis of 
the pharmacokinetic (PK) 
samples.LabCorp will serve as the Acentral 
laboratory will be used for clinical 
laboratory analysis. A testing 
laboratory Nuvisan will be responsible 
for analysis of the pharmacokinetic (PK) samples.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N72/75Change Section Page Previous Wording New Wording
Text was 
made more 
generic.2 Sponsor, 
Investigators 
and Study 
Administrative 
Structure18 The Sponsorâ€™s Clinical Trial 
Supplies department will supply 
the investigational medicinal 
product (IMP) to the study 
centers.The Sponsorâ€™s Clinical Trial Supplies 
department will supply The Sponsor 
will arrange delivery of the 
investigational medicinal product (IMP) to the study centers.
Matching 
criteria was 
changed so that matches 
can be 
identified before the last moderate 
hepatic 
impairment subject is 
identified.5.1 Overall 
Study Design 
and Plan23 Part 1 will include subjects with 
hepatic impairment (Child-Pugh 
class A [6 subjects] and Child Pugh class B [6 subjects]) and a 
control group (6 healthy 
subjects matched to 6 subjects
with Child-Pugh class B).Part 1 will include subjects with hepatic 
impairment (Child-Pugh class A [6 
subjects] and Child Pugh class B [6 subjects]) and a control group (6 
healthy subjects matched 1:1to [ADDRESS_46077] to mean age Â± 10 years, mean weight Â± 10 kg, and same gender ).
Figure 1 
Design Diagram was 
modifiedFigure 1 Design 
Diagram24 â€˜One Protocol â€“ One Reportâ€™ box was 
deleted.
Matching 
criteria was 
changed so that matches can be 
identified 
before the last moderate hepatic 
impairment 
subject is 
identified.5.[ADDRESS_46078] of 
6 subjects with normal hepatic function, matched to the subjects with moderate (Child-Pugh class B) impaired hepatic 
function with regard to mean 
age Â± 10 years, mean weight Â± 
[ADDRESS_46079] of 6 healthy subjects with normal hepatic 
function, matched 1:1to the subjects 
with moderate (Child-Pugh class B) 
impaired hepatic function with regard to 
mean age Â± 10 years, mean weight Â± 
10 kg, and same gender.
Text was made more 
generic for 
the 
bioanalytical 
assay.5.2.3 Rationale 
for Endpoints28 An enantiomer selective 
bioanalytical assay is available, which analyzes tepotinib and the enantiomers in 1 run.An enantiomer selective A bioanalytical 
assay is available, which analyzes 
tepotinib and the enantiomers in 1 run.
Drug 
screening 
instructionswere clarified.5.3.1 Inclusion Criterion 630 For healthy subjects, a positive 
cannabinoid (THC) result on drugs of abuse screening may 
be repeated and if negative on 
repeat, the subject will be allowed to participate in the study. For subjects with hepatic 
impairment, a positive 
cannabinoid (THC) result on drugs of abuse screening will not be exclusionary (at 
Screening or Day -1) if the 
subject uses cannabinoids on 
medical recommendation.For healthy all subjects, a positive
negative cannabinoid (THC) result on 
drugs of abuse screening may be 
repeated and if negative on repeat, the 
subject will be allowed is required to 
participate in the study. If the result is 
positive, the Principal Investigator 
[INVESTIGATOR_43918]. For 
subjects with hepatic impairment, a 
positive cannabinoid (THC) result on drugs of abuse screening will not be 
exclusionary (at Screening or Day -1) if 
the subject uses cannabinoids on 
medical recommendation. In subjects 
with hepatic impairment, positive 
test for drugs used on medical 
recommendation will be not 
exclusionary.
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N73/75Change Section Page Previous Wording New Wording
Exclusion 
criterion 25 
was moved to 
â€œall subjectsâ€ 
to ensure that liver impaired participants 
have 
sufficient 
renal function 5.3.2 Exclusion 
Criterion 1330 Renal dysfunction (defined as 
creatinine clearance < 60 mL/minute, 
calculated by [CONTACT_43995]-Gault formula).
Text was 
amended to 
make the
study less 
restrictive for potential 
subjects.5.3.[ADDRESS_46080] 
Accountability38 - At the conclusion or termination of 
this trial, all used and unused IMP kits will be destroyed at the trial site 
according to local regulations and institutional guidelines. All used and unused medications will be carefully recorded and documented before destruction.
Blinding 
procedure 
was clarified for bioanalytical assay.6.10 Blinding 37 Not Applicable. Blinding is not applicable. (Note: the 
bioanalytical assay will be performed 
without knowledge of hepatic function group information. Access to hepatic function group 
information will be restricted and 
defined in a Data Access Plan). Not 
applicable.
Unscheduled 
safety 
laboratory 
retest at the 
discretion of the investigator 
during 
screening was added to 
the protocol7.4.[ADDRESS_46081] No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N74/75Change Section Page Previous Wording New Wording
Drug 
screening 
instructions were clarified.7.4.3 Clinical 
Laboratory 
Assessments, 
Table 4, 
footnote c47 For healthy subjects, a positive 
cannabinoid (THC) result on 
drugs of abuse screening may 
be repeated and if negative on 
repeat, the subject will be allowed to participate in the study. For subjects with hepatic 
impairment, a positive 
cannabinoid (THC) result on drugs of abuse screening will not be exclusionary (at 
Screening or Day -1) if the 
subject uses cannabinoids on 
medical recommendation.For healthy all subjects, a positive
negative cannabinoid (THC) result on 
drugs of abuse screening may be 
repeated and if negative on repeat, the 
subject will be allowed is required to 
participate in the study. If the result is 
positive, the Principal Investigator 
[INVESTIGATOR_43918]. For 
subjects with hepatic impairment, a 
positive cannabinoid (THC) result on drugs of abuse screening will not be 
exclusionary (at Screening or Day -1) if 
thehepatic-impaired subject uses 
cannabinoids on medical recommendation. In subjects with 
hepatic impairment, positive test for 
drugs used on medical recommendation will be not 
exclusionary.
Text was 
made more 
generic for 
the 
bioanalytical 
assay.7.5.1 Body 
Fluids49 All sample analyses will be 
performed using a validated enantioselective ultra-
performance liquid 
chromatography coupled to tandem high-definition mass spectrometry method measuring 
parent drug and metabolites in 1 
run.All sample analyses will be performed 
using a validated enantioselective ultra-
performance liquid chromatography 
coupled to tandem high-definition mass 
spectrometry method measuring parent 
drug and metabolites in 1 run.
ODWG classification 
was added to 
the analysis.8.5.3 Analysis of 
Secondary 
Endpoints53 In a further analysis, the 
subjects with liver impairment 
will be evaluated according to the Albumin Bilirubin (ALBI) score (12).In a further analysis, the subjects with 
liver impairment will be evaluated 
according to the Albumin Bilirubin 
(ALBI) score and the Organ 
Dysfunction Working Group (ODWG) 
classification (12,13).
eCRF entry 
time was
aligned within site CTA language10.[ADDRESS_46082] left the 
study including any reason for 
early withdrawal from the study 
or IMP (if applicable).â€¢ Date that the subject left the study including any reason for early 
study discontinuation or withdrawal 
from IMP early withdrawal from the 
study or IMP (if applicable).
Text was 
made more 
generic.10.[ADDRESS_46083] Files57 The Monitor will be trained in 
INFORM (electronic database) 
and will have read-only access to the study data in INFORM for source data verification. Data 
reviewed can be signed off and 
queries issued directly in 
INFORM.The Monitor will be trained in INFORM 
(electronic database) to use the 
electronic database / eCRF and will 
have read-only access to the study data 
in INFORM the eCRF for source data 
verification. Data reviewed can be 
signed off and queries issued directly in 
INFORM the eCRF .
Do cu m e n t  No .   
Ob ject No .   EDEHIY
EDEHIH
Tepotinib (MSC2156119J) Tepotinib Hepatic Impairment Trial
MS200095-0028
C O N F I D E N T I A L
I N F O R M A T I O N75/75Change Section Page Previous Wording New Wording
Reference 
was added for 
ODWG classification11 References Cited in the Text59 - LoRusso PM, Venkatakrishnan K, 
Ramanathan RK, et al. 
Pharmacokinetics and safety of 
bortezomib in patients with 
advanced malignancies and varying degrees of liver dysfunction: Phase 1 NCI Organ Dysfunction Working 
Group study NCI-6432. Clin Cancer 
Res. 2012; 18(10), doi:10.1158/1078-
0432.CCR-11-2873.
Reference 
was added for 
Child-Pugh CriteriaTable 3 Child-
Pugh Criteria, 
11 References Cited in the Text26, 58, 59- Pugh RN, Murray-Lyon IM, Dawson 
JL, et. al. Transection of the 
oesophagus for bleeding 
oesophageal varices. Br J Surg. 
1973; 60:646. PMID: 4541913  
Child CG, Turcotte JG. The Liver and 
Portal Hypertension. Philadelphia, WB Saunders Co. 1964. NLMN: 
[ZIP_CODE]  
Trey C, Burns DG, Saunders SJ. 
Treatment of hepatic coma by 
[CONTACT_43994]. NEJM. 
1966; 274:473. PMID: [ADDRESS_46084] No .   EDEHIY
EDEHIH